

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 4, 2004, 07:55:13 ; Search time 329.893 Seconds
(without alignments)
180.798 Million cell updates/sec

Title: US-09-997-641-387

Perfect score: 1102

Sequence: 1 MLLFLVTAIAELCQPS.....ENGIPDLMDKGLMWS 212

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1155919 seqs, 281338677 residues

Total number of hits satisfying chosen parameters: 510

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%

Maximum Match 100%

Listing first 65000 summaries

Database :

Published Applications AA:*

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*

2: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*

3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*

4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*

5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*

6: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep:*

7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*

8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*

9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*

10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*

11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*

12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*

13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*

14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*

15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*

16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*

17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*

18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1102	100.0	212	9	US-09-989-722-387
2	1102	100.0	212	9	US-09-989-723-387
3	1102	100.0	212	9	US-09-989-723-387
4	1102	100.0	212	9	US-09-989-727-387
5	1102	100.0	212	9	US-09-989-731-387
6	1102	100.0	212	9	US-09-989-732-387
7	1102	100.0	212	9	US-09-991-073-387
8	1102	100.0	212	9	US-09-990-442-387
9	1102	100.0	212	9	US-09-991-163-387
10	1102	100.0	212	9	US-09-993-604-387
11	1102	100.0	212	9	US-09-990-456-387
12	1102	100.0	212	9	US-09-989-721-387
13	1102	100.0	212	9	US-09-992-598-387
14	1102	100.0	212	9	US-09-989-293A-387
15	1102	100.0	212	9	US-09-989-735-387

89	1102	100.0	212	12	US-10-157-798-482	Sequence 482, App	162	1102	100.0	212	14	US-10-127-842A-482	Sequence 482, App
90	1102	100.0	212	14	US-10-128-072-482	Sequence 482, App	163	1102	100.0	212	14	US-10-127-843A-482	Sequence 482, App
91	1102	100.0	212	14	US-10-1021-049-482	Sequence 482, App	164	1102	100.0	212	14	US-10-127-845A-482	Sequence 482, App
92	1102	100.0	212	14	US-10-123-904-482	Sequence 482, App	165	1102	100.0	212	14	US-10-127-846A-482	Sequence 482, App
93	1102	100.0	212	14	US-10-140-470-482	Sequence 482, App	166	1102	100.0	212	14	US-10-127-848A-482	Sequence 482, App
94	1102	100.0	212	14	US-10-175-746-482	Sequence 482, App	167	1102	100.0	212	14	US-10-127-849A-482	Sequence 482, App
95	1102	100.0	212	14	US-10-176-918-482	Sequence 482, App	168	1102	100.0	212	14	US-10-127-850A-482	Sequence 482, App
96	1102	100.0	212	14	US-10-176-921-482	Sequence 482, App	169	1102	100.0	212	14	US-10-127-851A-482	Sequence 482, App
97	1102	100.0	212	14	US-10-137-865-482	Sequence 482, App	170	1102	100.0	212	14	US-10-128-684A-482	Sequence 482, App
98	1102	100.0	212	14	US-10-140-474-482	Sequence 482, App	171	1102	100.0	212	14	US-10-128-686A-482	Sequence 482, App
99	1102	100.0	212	14	US-10-142-431-482	Sequence 482, App	172	1102	100.0	212	14	US-10-128-690A-482	Sequence 482, App
100	1102	100.0	212	14	US-10-143-114-482	Sequence 482, App	173	1102	100.0	212	14	US-10-128-691A-482	Sequence 482, App
101	1102	100.0	212	14	US-10-140-002-482	Sequence 482, App	174	1102	100.0	212	14	US-10-131-819A-482	Sequence 482, App
102	1102	100.0	212	14	US-10-142-419-482	Sequence 482, App	175	1102	100.0	212	14	US-10-131-822A-482	Sequence 482, App
103	1102	100.0	212	14	US-10-123-262-482	Sequence 482, App	176	1102	100.0	212	14	US-10-131-828A-482	Sequence 482, App
104	1102	100.0	212	14	US-10-142-423-482	Sequence 482, App	177	1102	100.0	212	14	US-10-131-836A-482	Sequence 482, App
105	1102	100.0	212	14	US-10-121-050-482	Sequence 482, App	178	1102	100.0	212	14	US-10-146-729-482	Sequence 482, App
106	1102	100.0	212	14	US-10-141-755-482	Sequence 482, App	179	1102	100.0	212	14	US-10-147-484-482	Sequence 482, App
107	1102	100.0	212	14	US-10-143-032-482	Sequence 482, App	180	1102	100.0	212	14	US-10-147-508-482	Sequence 482, App
108	1102	100.0	212	14	US-10-123-108-482	Sequence 482, App	181	1102	100.0	212	14	US-10-147-512-482	Sequence 482, App
109	1102	100.0	212	14	US-10-123-236-482	Sequence 482, App	182	1102	100.0	212	14	US-10-175-735-482	Sequence 482, App
110	1102	100.0	212	14	US-10-123-261-482	Sequence 482, App	183	1102	100.0	212	14	US-10-121-040-482	Sequence 482, App
111	1102	100.0	212	14	US-10-140-921-482	Sequence 482, App	184	1102	100.0	212	14	US-10-121-056-482	Sequence 482, App
112	1102	100.0	212	14	US-10-140-928-482	Sequence 482, App	185	1102	100.0	212	14	US-10-121-061-482	Sequence 482, App
113	1102	100.0	212	14	US-10-121-045-482	Sequence 482, App	186	1102	100.0	212	14	US-10-123-235-482	Sequence 482, App
114	1102	100.0	212	14	US-10-123-293-482	Sequence 482, App	187	1102	100.0	212	14	US-10-124-818-482	Sequence 482, App
115	1102	100.0	212	14	US-10-127-825A-482	Sequence 482, App	188	1102	100.0	212	14	US-10-137-868-482	Sequence 482, App
116	1102	100.0	212	14	US-10-124-819-482	Sequence 482, App	189	1102	100.0	212	14	US-10-147-492-482	Sequence 482, App
117	1102	100.0	212	14	US-10-124-822-482	Sequence 482, App	190	1102	100.0	212	14	US-10-158-782-482	Sequence 482, App
118	1102	100.0	212	14	US-10-140-925-482	Sequence 482, App	191	1102	100.0	212	14	US-10-123-905-482	Sequence 482, App
119	1102	100.0	212	14	US-10-160-498-482	Sequence 482, App	192	1102	100.0	212	14	US-10-123-907-482	Sequence 482, App
120	1102	100.0	212	14	US-10-124-824-482	Sequence 482, App	193	1102	100.0	212	14	US-10-124-815-482	Sequence 482, App
121	1102	100.0	212	14	US-10-127-825A-482	Sequence 482, App	194	1102	100.0	212	14	US-10-125-921A-482	Sequence 482, App
122	1102	100.0	212	14	US-10-127-828A-482	Sequence 482, App	195	1102	100.0	212	14	US-10-125-928A-482	Sequence 482, App
123	1102	100.0	212	14	US-10-127-835A-482	Sequence 482, App	196	1102	100.0	212	14	US-10-127-821A-482	Sequence 482, App
124	1102	100.0	212	14	US-10-127-839A-482	Sequence 482, App	197	1102	100.0	212	14	US-10-127-822A-482	Sequence 482, App
125	1102	100.0	212	14	US-10-127-901A-482	Sequence 482, App	198	1102	100.0	212	14	US-10-127-826A-482	Sequence 482, App
126	1102	100.0	212	14	US-10-128-693A-482	Sequence 482, App	199	1102	100.0	212	14	US-10-127-827A-482	Sequence 482, App
127	1102	100.0	212	14	US-10-131-813A-482	Sequence 482, App	200	1102	100.0	212	14	US-10-127-828A-482	Sequence 482, App
128	1102	100.0	212	14	US-10-131-818A-482	Sequence 482, App	201	1102	100.0	212	14	US-10-127-830A-482	Sequence 482, App
129	1102	100.0	212	14	US-10-131-823A-482	Sequence 482, App	202	1102	100.0	212	14	US-10-127-832A-482	Sequence 482, App
130	1102	100.0	212	14	US-10-131-824A-482	Sequence 482, App	203	1102	100.0	212	14	US-10-127-833A-482	Sequence 482, App
131	1102	100.0	212	14	US-10-131-830A-482	Sequence 482, App	204	1102	100.0	212	14	US-10-127-834A-482	Sequence 482, App
132	1102	100.0	212	14	US-10-131-837A-482	Sequence 482, App	205	1102	100.0	212	14	US-10-127-836A-482	Sequence 482, App
133	1102	100.0	212	14	US-10-137-872A-482	Sequence 482, App	206	1102	100.0	212	14	US-10-127-841A-482	Sequence 482, App
134	1102	100.0	212	14	US-10-147-500-482	Sequence 482, App	207	1102	100.0	212	14	US-10-127-844A-482	Sequence 482, App
135	1102	100.0	212	14	US-10-147-502-482	Sequence 482, App	208	1102	100.0	212	14	US-10-128-687A-482	Sequence 482, App
136	1102	100.0	212	14	US-10-147-515-482	Sequence 482, App	209	1102	100.0	212	14	US-10-128-688A-482	Sequence 482, App
137	1102	100.0	212	14	US-10-147-517-482	Sequence 482, App	210	1102	100.0	212	14	US-10-128-689A-482	Sequence 482, App
138	1102	100.0	212	14	US-10-147-526-482	Sequence 482, App	211	1102	100.0	212	14	US-10-128-694A-482	Sequence 482, App
139	1102	100.0	212	14	US-10-147-527-482	Sequence 482, App	212	1102	100.0	212	14	US-10-128-698A-482	Sequence 482, App
140	1102	100.0	212	14	US-10-121-041-482	Sequence 482, App	213	1102	100.0	212	14	US-10-131-825A-482	Sequence 482, App
141	1102	100.0	212	14	US-10-121-043-482	Sequence 482, App	214	1102	100.0	212	14	US-10-131-828A-482	Sequence 482, App
142	1102	100.0	212	14	US-10-121-047-482	Sequence 482, App	215	1102	100.0	212	14	US-10-131-835A-482	Sequence 482, App
143	1102	100.0	212	14	US-10-123-215-482	Sequence 482, App	216	1102	100.0	212	14	US-10-131-817A-482	Sequence 482, App
144	1102	100.0	212	14	US-10-123-902-482	Sequence 482, App	217	1102	100.0	212	14	US-10-131-821A-482	Sequence 482, App
145	1102	100.0	212	14	US-10-123-908-482	Sequence 482, App	218	1102	100.0	212	14	US-10-131-822A-482	Sequence 482, App
146	1102	100.0	212	14	US-10-123-909-482	Sequence 482, App	219	1102	100.0	212	14	US-10-131-828A-482	Sequence 482, App
147	1102	100.0	212	14	US-10-123-910-482	Sequence 482, App	220	1102	100.0	212	14	US-10-131-835A-482	Sequence 482, App
148	1102	100.0	212	14	US-10-124-813-482	Sequence 482, App	221	1102	100.0	212	14	US-10-137-864A-482	Sequence 482, App
149	1102	100.0	212	14	US-10-124-817-482	Sequence 482, App	222	1102	100.0	212	14	US-10-137-869A-482	Sequence 482, App
150	1102	100.0	212	14	US-10-125-922-482	Sequence 482, App	223	1102	100.0	212	14	US-10-147-523-482	Sequence 482, App
151	1102	100.0	212	14	US-10-125-924-482	Sequence 482, App	224	1102	100.0	212	14	US-10-158-785-482	Sequence 482, App
152	1102	100.0	212	14	US-10-140-860-482	Sequence 482, App	225	1102	100.0	212	14	US-10-121-051-482	Sequence 482, App
153	1102	100.0	212	14	US-10-142-417-482	Sequence 482, App	226	1102	100.0	212	14	US-10-121-042-482	Sequence 482, App
154	1102	100.0	212	14	US-10-147-519-482	Sequence 482, App	227	1102	100.0	212	14	US-10-123-312-482	Sequence 482, App
155	1102	100.0	212	14	US-10-157-782-482	Sequence 482, App	228	1102	100.0	212	14	US-10-132-007-482	Sequence 482, App
156	1102	100.0	212	14	US-10-152-395-482	Sequence 482, App	229	1102	100.0	212	14	US-10-194-359-482	Sequence 482, App
157	1102	100.0	212	14	US-10-125-926A-482	Sequence 482, App	230	1102	100.0	212	14	US-10-127-847A-482	Sequence 482, App
158	1102	100.0	212	14	US-10-125-930A-482	Sequence 482, App	231	1102	100.0	212	14	US-10-175-590-482	Sequence 482, App
159	1102	100.0	212	14	US-10-127-831A-482	Sequence 482, App	232	1102	100.0	212	14	US-10-137-866-482	Sequence 482, App
160	1102	100.0	212	14	US-10-127-837A-482	Sequence 482, App	233	1102	100.0	212	14	US-10-146-726-482	Sequence 482, App
161	1102	100.0	212	14	US-10-127-838B-482	Sequence 482, App	234	1102	100.0	212	14	US-10-146-727-482	Sequence 482, App

381	1102	100.0	212	14	US-10-147-493-482	Sequence 482, App
382	1102	100.0	212	14	US-10-147-496-482	Sequence 482, App
383	1102	100.0	212	14	US-10-147-505-482	Sequence 482, App
384	1102	100.0	212	14	US-10-147-516-482	Sequence 482, App
385	1102	100.0	212	14	US-10-152-398-482	Sequence 482, App
386	1102	100.0	212	14	US-10-152-398-482	Sequence 482, App
387	1102	100.0	212	14	US-10-145-750-482	Sequence 482, App
388	1102	100.0	212	14	US-10-152-373-482	Sequence 482, App
389	1102	100.0	212	14	US-10-121-044-482	Sequence 482, App
390	1102	100.0	212	14	US-10-121-055-482	Sequence 482, App
391	1102	100.0	212	14	US-10-121-057-482	Sequence 482, App
392	1102	100.0	212	14	US-10-121-058-482	Sequence 482, App
393	1102	100.0	212	14	US-10-121-059-482	Sequence 482, App
394	1102	100.0	212	14	US-10-121-060-482	Sequence 482, App
395	1102	100.0	212	14	US-10-123-109-482	Sequence 482, App
396	1102	100.0	212	14	US-10-123-154-482	Sequence 482, App
397	1102	100.0	212	14	US-10-123-157-482	Sequence 482, App
398	1102	100.0	212	14	US-10-123-906-482	Sequence 482, App
399	1102	100.0	212	14	US-10-124-814-482	Sequence 482, App
400	1102	100.0	212	14	US-10-124-816-482	Sequence 482, App
401	1102	100.0	212	14	US-10-124-820-482	Sequence 482, App
402	1102	100.0	212	14	US-10-125-704-482	Sequence 482, App
403	1102	100.0	212	14	US-10-125-927-482	Sequence 482, App
404	1102	100.0	212	14	US-10-142-889-482	Sequence 482, App
405	1102	100.0	212	14	US-10-145-874-482	Sequence 482, App
406	1102	100.0	212	14	US-10-147-497-482	Sequence 482, App
407	1102	100.0	212	14	US-10-152-371-482	Sequence 482, App
408	1102	100.0	212	14	US-10-152-374-482	Sequence 482, App
409	1102	100.0	212	14	US-10-152-375-482	Sequence 482, App
410	1102	100.0	212	14	US-10-152-377-482	Sequence 482, App
411	1102	100.0	212	14	US-10-152-386-482	Sequence 482, App
412	1102	100.0	212	14	US-10-153-391-482	Sequence 482, App
413	1102	100.0	212	14	US-10-153-399-482	Sequence 482, App
414	1102	100.0	212	14	US-10-156-848-482	Sequence 482, App
415	1102	100.0	212	14	US-10-157-785-482	Sequence 482, App
416	1102	100.0	212	14	US-10-157-796-482	Sequence 482, App
417	1102	100.0	212	14	US-10-157-796-482	Sequence 482, App
418	1102	100.0	212	14	US-10-160-500-482	Sequence 482, App
419	1102	100.0	212	14	US-10-121-046-482	Sequence 482, App
420	1102	100.0	212	14	US-10-123-214-482	Sequence 482, App
421	1102	100.0	212	14	US-10-123-214-482	Sequence 482, App
422	1102	100.0	212	14	US-10-123-805-482	Sequence 482, App
423	1102	100.0	212	14	US-10-124-821-482	Sequence 482, App
424	1102	100.0	212	14	US-10-152-385-482	Sequence 482, App
425	1102	100.0	212	14	US-10-153-393-482	Sequence 482, App
426	1102	100.0	212	14	US-10-153-396-482	Sequence 482, App
427	1102	100.0	212	14	US-10-153-553-482	Sequence 482, App
428	1102	100.0	212	14	US-10-153-840-482	Sequence 482, App
429	1102	100.0	212	14	US-10-156-841-482	Sequence 482, App
430	1102	100.0	212	14	US-10-156-842-482	Sequence 482, App
431	1102	100.0	212	14	US-10-156-844-482	Sequence 482, App
432	1102	100.0	212	14	US-10-156-845-482	Sequence 482, App
433	1102	100.0	212	14	US-10-156-845-482	Sequence 482, App
434	1102	100.0	212	14	US-10-121-048-482	Sequence 482, App
435	1102	100.0	212	14	US-10-121-053-482	Sequence 482, App
436	1102	100.0	212	14	US-10-121-053-482	Sequence 482, App
437	1102	100.0	212	14	US-10-121-054-482	Sequence 482, App
438	1102	100.0	212	14	US-10-121-063-482	Sequence 482, App
439	1102	100.0	212	14	US-10-123-212-482	Sequence 482, App
440	1102	100.0	212	14	US-10-123-213-482	Sequence 482, App
441	1102	100.0	212	14	US-10-123-291-482	Sequence 482, App
442	1102	100.0	212	14	US-10-123-322-482	Sequence 482, App
443	1102	100.0	212	14	US-10-123-771-482	Sequence 482, App
444	1102	100.0	212	14	US-10-123-911-482	Sequence 482, App
445	1102	100.0	212	14	US-10-124-823-482	Sequence 482, App
446	1102	100.0	212	14	US-10-125-931-482	Sequence 482, App
447	1102	100.0	212	14	US-10-125-933-482	Sequence 482, App
448	1102	100.0	212	15	US-10-123-913-482	Sequence 482, App
449	1102	100.0	212	15	US-10-140-806-482	Sequence 482, App
450	1102	100.0	212	15	US-10-140-806-482	Sequence 482, App
451	1102	100.0	212	15	US-10-140-810-482	Sequence 482, App
452	1102	100.0	212	15	US-10-140-863-482	Sequence 482, App
453	1102	100.0	212	15	US-10-141-699-482	Sequence 482, App
454	1102	100.0	212	15	US-10-141-703-482	Sequence 482, App
455	1102	100.0	212	15	US-10-141-706-482	Sequence 482, App
456	1102	100.0	212	15	US-10-141-752-482	Sequence 482, App
457	1102	100.0	212	15	US-10-141-757-482	Sequence 482, App
458	1102	100.0	212	15	US-10-142-428-482	Sequence 482, App
459	1102	100.0	212	15	US-10-142-428-482	Sequence 482, App
460	1102	100.0	212	15	US-10-142-884-482	Sequence 482, App
461	1102	100.0	212	15	US-10-143-027-482	Sequence 482, App
462	1102	100.0	212	15	US-10-143-115-482	Sequence 482, App
463	1102	100.0	212	15	US-10-144-956-482	Sequence 482, App
464	1102	100.0	212	15	US-10-144-958-482	Sequence 482, App
465	1102	100.0	212	15	US-10-145-632-482	Sequence 482, App
466	1102	100.0	212	15	US-10-145-749-482	Sequence 482, App
467	1102	100.0	212	15	US-10-145-753-482	Sequence 482, App
468	1102	100.0	212	15	US-10-145-871-482	Sequence 482, App
469	1102	100.0	212	15	US-10-145-878-482	Sequence 482, App
470	1102	100.0	212	15	US-10-146-794-482	Sequence 482, App
471	1102	100.0	212	15	US-10-147-489-482	Sequence 482, App
472	1102	100.0	212	15	US-10-147-507-482	Sequence 482, App
473	1102	100.0	212	15	US-10-147-535-482	Sequence 482, App
474	1102	100.0	212	15	US-10-147-537-482	Sequence 482, App
475	1102	100.0	212	15	US-10-152-376-482	Sequence 482, App
476	1102	100.0	212	15	US-10-152-381-482	Sequence 482, App
477	1102	100.0	212	15	US-10-152-400-482	Sequence 482, App
478	1102	100.0	212	15	US-10-153-585-482	Sequence 482, App
479	1102	100.0	212	15	US-10-157-800-482	Sequence 482, App
480	1102	100.0	212	15	US-10-157-800-482	Sequence 482, App
481	1102	100.0	212	15	US-10-157-801-482	Sequence 482, App
482	1102	100.0	212	15	US-10-157-802-482	Sequence 482, App
483	1102	100.0	212	15	US-10-158-784-482	Sequence 482, App
484	1102	100.0	212	15	US-10-158-789-482	Sequence 482, App
485	1102	100.0	212	15	US-10-192-011-482	Sequence 482, App
486	1102	100.0	212	15	US-10-139-963-482	Sequence 482, App
487	1102	100.0	212	15	US-10-140-020-482	Sequence 482, App
488	1102	100.0	212	15	US-10-140-023-482	Sequence 482, App
489	1102	100.0	212	15	US-10-140-809-482	Sequence 482, App
490	1102	100.0	212	15	US-10-140-865-482	Sequence 482, App
491	1102	100.0	212	15	US-10-141-701-482	Sequence 482, App
492	1102	100.0	212	15	US-10-141-754-482	Sequence 482, App
493	1102	100.0	212	15	US-10-141-760-482	Sequence 482, App
494	1102	100.0	212	15	US-10-142-425-482	Sequence 482, App
495	1102	100.0	212	15	US-10-142-430-482	Sequence 482, App
496	1102	100.0	212	15	US-10-143-113-482	Sequence 482, App
497	1102	100.0	212	15	US-10-146-730-482	Sequence 482, App
498	1102	100.0	212	15	US-10-146-792-482	Sequence 482, App
499	1102	100.0	212	15	US-10-158-791-482	Sequence 482, App
500	1102	100.0	212	15	US-10-156-843-482	Sequence 482, App
501	1102	100.0	212	15	US-10-157-786-482	Sequence 387, App
502	1102	100.0	212	15	US-10-219-538-387	Sequence 482, App
503	1102	100.0	212	15	US-10-147-528-482	Sequence 482, App
504	1102	100.0	212	15	US-10-128-692A-482	Sequence 482, App
505	1102	100.0	212	15	US-10-147-527-482	Sequence 482, App
506	1102	100.0	212	16	US-10-147-536-482	Sequence 482, App
507	1073	97.4	222	12	US-10-372-876-141	Sequence 141, App
508	1073	97.4	222	14	US-10-097-065-141	Sequence 129, App
509	1056	96.7	222	10	US-09-948-783-129	Sequence 138, App
510	1056	96.7	223	10	US-09-892-877-128	

ALIGNMENTS

RESULT 1
US-09-989-722-387
; Sequence 387, Application US/09989722
; Patent No. US20020072067A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Ben J.
; APPLICANT: Ferrara, Napoleone

```
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P330R1C445
; CURRENT APPLICATION NUMBER: US/10/157,786
; CURRENT FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 482
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Homo Sapien
; US-10-157-786-482

Query Match 100.0%; Score 1102; DB 15; Length 212;
Best Local Similarity 100.0%; Pred. No. 4.8e-113;
Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWLLFVLTAIHAELCQPGAENAFKVRISIRITAGDKAYAWDTNBEYLFKAWAFSMRK 60
DB 1 MLWLLFVLTAIHAELCQPGAENAFKVRISIRITAGDKAYAWDTNBEYLFKAWAFSMRK 60
QY 61 VPRREATEISHVLLCNVTQVSFWFVWTDPSKNHTLPAAVEVQSAIRMNKNRINNAFFLND 120
DB 61 VPRREATEISHVLLCNVTQVSFWFVWTDPSKNHTLPAAVEVQSAIRMNKNRINNAFFLND 120
QY 121 QTLFLKIPSTLAPPMDPSVPWIIIFGVIFCIIIVAIALLILSGIWQRRRKNKEPSEVD 180
DB 121 QTLFLKIPSTLAPPMDPSVPWIIIFGVIFCIIIVAIALLILSGIWQRRRKNKEPSEVD 180
QY 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212
DB 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212

RESULT 502
US-10-219-538-387
; Sequence 387, Application US/10219538
; Publication No. US20030219856A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker, Kevin
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin
; APPLICANT: Kljavin, Ivar
; APPLICANT: Napier, Mary
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C73
; CURRENT APPLICATION NUMBER: US/10/219,538
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: US 09/941,992
; PRIOR FILING DATE: 2001-08-28
; PRIOR APPLICATION NUMBER: PCT/US00/08439
; PRIOR FILING DATE: 2000-03-30
; PRIOR APPLICATION NUMBER: PCT/US99/12252
; PRIOR FILING DATE: 1999-06-02
```

```
; PRIOR APPLICATION NUMBER: US 09/380,137
; PRIOR FILING DATE: 1999-08-25
; PRIOR APPLICATION NUMBER: US 60/141,037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 60/092,182
; PRIOR FILING DATE: 1998-07-09
; NUMBER OF SEQ ID NOS: 532
; SEQ ID NO 387
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-219-538-387

Query Match 100.0%; Score 1102; DB 15; Length 212;
Best Local Similarity 100.0%; Pred. No. 4.8e-113;
Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWLLFVLTAIHAELCQPGAENAFKVRISIRITAGDKAYAWDTNBEYLFKAWAFSMRK 60
DB 1 MLWLLFVLTAIHAELCQPGAENAFKVRISIRITAGDKAYAWDTNBEYLFKAWAFSMRK 60
QY 61 VPRREATEISHVLLCNVTQVSFWFVWTDPSKNHTLPAAVEVQSAIRMNKNRINNAFFLND 120
DB 61 VPRREATEISHVLLCNVTQVSFWFVWTDPSKNHTLPAAVEVQSAIRMNKNRINNAFFLND 120
QY 121 QTLFLKIPSTLAPPMDPSVPWIIIFGVIFCIIIVAIALLILSGIWQRRRKNKEPSEVD 180
DB 121 QTLFLKIPSTLAPPMDPSVPWIIIFGVIFCIIIVAIALLILSGIWQRRRKNKEPSEVD 180
QY 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212
DB 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212

RESULT 503
US-10-147-528-482
; Sequence 482, Application US/10147528
; Publication No. US20030219885A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C334
; CURRENT APPLICATION NUMBER: US/10/147,528
; CURRENT FILING DATE: 2002-05-16
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 482
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Homo Sapien
; US-10-147-528-482

Query Match 100.0%; Score 1102; DB 15; Length 212;
Best Local Similarity 100.0%; Pred. No. 4.8e-113;
Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 MLWLLFFLVTAIHAELCPGAEAFKVRLSIRLTALGDKAYAWDTNEEYLFKAMVAFSRK 60
DB 1 MLWLLFFLVTAIHAELCPGAEAFKVRLSIRLTALGDKAYAWDTNEEYLFKAMVAFSRK 60
QY 61 VPREATEISHVLLCNVTQVSFWFVVDPSKNHTLPAVEVQSAIRMNKNRINNNAFFLND 120
DB 61 VPREATEISHVLLCNVTQVSFWFVVDPSKNHTLPAVEVQSAIRMNKNRINNNAFFLND 120
QY 121 QTLFELKIPSTLAPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKEPSEVD 180
DB 121 QTLFELKIPSTLAPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKEPSEVD 180
QY 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212
DB 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212
```

RESULT 504

```
US-10-128-692A-482
; Sequence 482, Application US/10128692A
; Publication No. US20040009547A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Pilvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C124
; CURRENT APPLICATION NUMBER: US/10/128,692A
; PRIORITY FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining prior application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 482
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Homo Sapien
```

US-10-128-692A-482

```
Best Local Similarity 100.0%; Pred. No. 4.8e-113;
Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MLWLLFFLVTAIHAELCPGAEAFKVRLSIRLTALGDKAYAWDTNEEYLFKAMVAFSRK 60
DB 1 MLWLLFFLVTAIHAELCPGAEAFKVRLSIRLTALGDKAYAWDTNEEYLFKAMVAFSRK 60
QY 61 VPREATEISHVLLCNVTQVSFWFVVDPSKNHTLPAVEVQSAIRMNKNRINNNAFFLND 120
DB 61 VPREATEISHVLLCNVTQVSFWFVVDPSKNHTLPAVEVQSAIRMNKNRINNNAFFLND 120
QY 121 QTLFELKIPSTLAPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKEPSEVD 180
DB 121 QTLFELKIPSTLAPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKEPSEVD 180
QY 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212
DB 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212
```

RESULT 505

```
US-10-140-927-482
; Sequence 482, Application US/10140927
; Publication No. US20040009548A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Pilvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C180
; CURRENT APPLICATION NUMBER: US/10/140,927
; PRIORITY FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 482
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Homo Sapien
```

```
Query Match
Best Local Similarity 100.0%; Pred. No. 4.8e-113;
Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MLWLLFFLVTAIHAELCPGAEAFKVRLSIRLTALGDKAYAWDTNEEYLFKAMVAFSRK 60
DB 1 MLWLLFFLVTAIHAELCPGAEAFKVRLSIRLTALGDKAYAWDTNEEYLFKAMVAFSRK 60
QY 61 VPREATEISHVLLCNVTQVSFWFVVDPSKNHTLPAVEVQSAIRMNKNRINNNAFFLND 120
DB 61 VPREATEISHVLLCNVTQVSFWFVVDPSKNHTLPAVEVQSAIRMNKNRINNNAFFLND 120
QY 121 QTLFELKIPSTLAPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKEPSEVD 180
DB 121 QTLFELKIPSTLAPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKEPSEVD 180
QY 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212
```

```
Db 181 DAEDKCNMTIENGIPSDPLDMKGGILMPS 212

RESULT 506
US-10-147-536-482
; Sequence 482, Application US/10147536
; Publication No. US20040077064A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C349
; CURRENT APPLICATION NUMBER: US/10/147,536
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 482
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-147-536-482

Query Match 100.0%; Score 1102; DB 16; Length 212;
Best Local Similarity 100.0%; Pred. No. 4.8e-113;
Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWLLFFLVTAIHAELCQPGAENAFKVRISIRLTALGDKAYAWDTNTEYILFKAMVAFSMRK 60
Db 1 MLWLLFFLVTAIHAELCQPGAENAFKVRISIRLTALGDKAYAWDTNTEYILFKAMVAFSMRK 60

QY 61 VPRREATEISHVLLCNVTQVSFWVVDPSKNHTLPAVEVQSAIRMNKNRINNAPFLND 120
Db 61 VPRREATEISHVLLCNVTQVSFWVVDPSKNHTLPAVEVQSAIRMNKNRINNAPFLND 120

QY 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRKNKPESEVD 180
Db 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRKNKPESEVD 180

QY 181 DAEDKCNMTIENGIPSDPLDMKGGILMPS 212
Db 181 DAEDKCNMTIENGIPSDPLDMKGGILMPS 212

RESULT 507
US-10-372-876-141
; Sequence 141, Application US/10372876
; Publication No. US20030204071A1
; GENERAL INFORMATION:
; APPLICANT: Moore, Paul A. et al.
; TITLE OF INVENTION: 110 Human Secreted Proteins
; FILE REFERENCE: P2021P1
; CURRENT APPLICATION NUMBER: US/10/372,876
; CURRENT FILING DATE: 2003-02-26
; Prior Application Number: 09/334,595
; Prior Filing Date: 1999-06-17
; Prior Application Number: PCT/US98/27059
; Prior Filing Date: 1998-12-17
```

```
; PRIOR APPLICATION NUMBER: 60/070,923
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,007
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,057
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,006
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,369
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/068,367
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/068,368
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/068,169
; PRIOR FILING DATE: 1997-12-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 672
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 141
; LENGTH: 222
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-372-876-141

Query Match 97.4%; Score 1073; DB 12; Length 222;
Best Local Similarity 100.0%; Pred. No. 8.1e-110;
Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWLLFFLVTAIHAELCQPGAENAFKVRISIRLTALGDKAYAWDTNTEYILFKAMVAFSMRK 60
Db 1 MLWLLFFLVTAIHAELCQPGAENAFKVRISIRLTALGDKAYAWDTNTEYILFKAMVAFSMRK 60

QY 61 VPRREATEISHVLLCNVTQVSFWVVDPSKNHTLPAVEVQSAIRMNKNRINNAPFLND 120
Db 61 VPRREATEISHVLLCNVTQVSFWVVDPSKNHTLPAVEVQSAIRMNKNRINNAPFLND 120

QY 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRKNKPESEVD 180
Db 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRKNKPESEVD 180

QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
Db 181 DAEDKCNMTIENGIPSDPLDMKGG 206

RESULT 508
US-10-097-065-141
; Sequence 141, Application US/10097065
; Publication No. US20030055236A1
; GENERAL INFORMATION:
; APPLICANT: Moore, Paul A. et al.
; TITLE OF INVENTION: 110 Human Secreted Proteins
; FILE REFERENCE: P2021P1
; CURRENT APPLICATION NUMBER: US/10/097,065
; CURRENT FILING DATE: 2002-03-14
; PRIOR APPLICATION NUMBER: PCT/US98/27059
; PRIOR FILING DATE: 1998-12-17
; PRIOR APPLICATION NUMBER: 60/070,923
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,007
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,057
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,006
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,369
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/068,367
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/068,368
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/068,169
```

PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/068,053
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,064
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,054
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,008
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,365
PRIOR FILING DATE: 1997-12-19
NUMBER OF SEQ ID NOS: 672
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 141
LENGTH: 222
TYPE: PRT
ORGANISM: Homo sapiens
US-10-097-065-141

Query Match 97.4%; Score 1073; DB 14; Length 222;
Best Local Similarity 100.0%; Pred. No. 8.1e-110;
Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWLLFFLVTAHAEHCQGAENAFKVLRSITLALGDKAYAWDTNVEYLFKAWAFPSMRK 60
DB 1 MLWLLFFLVTAHAEHCQGAENAFKVLRSITLALGDKAYAWDTNVEYLFKAWAFPSMRK 60

QY 61 VNRREATEISHVLLCNVTQVSFVFWVVDPSKNHTLPAVEVQSAIRMNKNRINNAFFLND 120
DB 61 VNRREATEISHVLLCNVTQVSFVFWVVDPSKNHTLPAVEVQSAIRMNKNRINNAFFLND 120

QY 121 QTEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIVAIALLILSGIWORRRKNKEPSEVD 180
DB 121 QTEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIVAIALLILSGIWORRRKNKEPSEVD 180

QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
DB 181 DAEDKCNMTIENGIPSDPLDMKGG 206

RESULT 509
US-09-948-783-129
Sequence 129, Application US/09948783
Publication No. US20030100051A1
GENERAL INFORMATION:
APPLICANT: Ruben et. al.
TITLE OF INVENTION: 97 Human secreted proteins
FILE REFERENCE: PZ028P2
CURRENT APPLICATION NUMBER: US/09/948,783
PRIOR FILING DATE: 2001-09-10
PRIOR APPLICATION NUMBER: 60/231,846
PRIOR FILING DATE: 2000-09-11
PRIOR APPLICATION NUMBER: 09/892,877
PRIOR FILING DATE: 2001-08-28
PRIOR APPLICATION NUMBER: 09/437,658
PRIOR FILING DATE: 1998-11-10
PRIOR APPLICATION NUMBER: PCT/US99/09847
PRIOR FILING DATE: 1999-05-06
PRIOR APPLICATION NUMBER: 60/085,093
PRIOR FILING DATE: 1998-05-12
PRIOR APPLICATION NUMBER: 60/085,094
PRIOR FILING DATE: 1998-05-12
PRIOR APPLICATION NUMBER: 60/085,105
PRIOR FILING DATE: 1998-05-12
PRIOR APPLICATION NUMBER: 60/085,180
PRIOR FILING DATE: 1998-05-12
PRIOR APPLICATION NUMBER: 60/085,927
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,906
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,924
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,922

PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,921
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,923
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,925
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,928
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,920
PRIOR FILING DATE: 1998-05-18
NUMBER OF SEQ ID NOS: 465
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 129
LENGTH: 222
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: SITE
LOCATION: (120)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-948-783-129

Query Match 96.7%; Score 1066; DB 10; Length 222;
Best Local Similarity 99.5%; Pred. No. 4.8e-109;
Matches 205; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MLWLLFFLVTAHAEHCQGAENAFKVLRSITLALGDKAYAWDTNVEYLFKAWAFPSMRK 60
DB 1 MLWLLFFLVTAHAEHCQGAENAFKVLRSITLALGDKAYAWDTNVEYLFKAWAFPSMRK 60

QY 61 VNRREATEISHVLLCNVTQVSFVFWVVDPSKNHTLPAVEVQSAIRMNKNRINNAFFLND 120
DB 61 VNRREATEISHVLLCNVTQVSFVFWVVDPSKNHTLPAVEVQSAIRMNKNRINNAFFLND 120

QY 121 QTEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIVAIALLILSGIWORRRKNKEPSEVD 180
DB 121 QTEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIVAIALLILSGIWORRRKNKEPSEVD 180

QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
DB 181 DAEDKCNMTIENGIPSDPLDMKGG 206

RESULT 510
US-09-892-877-128
Sequence 128, Application US/09892877
Publication No. US20030077809A1
GENERAL INFORMATION:
APPLICANT: Ruben et. al.
TITLE OF INVENTION: 97 Human secreted proteins
FILE REFERENCE: PZ028P1
CURRENT APPLICATION NUMBER: US/09/892,877
PRIOR FILING DATE: 2001-06-28
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/437,658
PRIOR FILING DATE: EARLIER FILING DATE: 1999-11-10
NUMBER OF SEQ ID NOS: 461
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 128
LENGTH: 223
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: SITE
LOCATION: (120)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-892-877-128

Query Match 96.7%; Score 1066; DB 10; Length 223;
Best Local Similarity 99.5%; Pred. No. 4.8e-109;

Matches		205;	Conservative	0;	Mismatches	1;	Indels	0;	Gaps	0;
Qy	1	MLWLLFELVTAIHAELCQPGAENAFKVRLSIR	TALGDKAYAWDTN	EEYLFKAMVAFSMRK	60					
Db	1	MLWLLFELVTAIHAELCQPGAENAFKVRLSIR	TALGDKAYAWDTN	EEYLFKAMVAFSMRK	60					
Qy	61	VPNEATEISHVLLCNVTQVSFWVVTDP	SKNHTLPAVEVQSAIR	MKNKRINNAFELND	120					
Db	61	VPNEATEISHVLLCNVTQVSFWVVTDP	SKNHTLPAVEVQSAIR	MKNKRINNAFELNK	120					
Qy	121	QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCII	IIIVAIALLSGI	WRRRKNKEPSEVD	180					
Db	121	QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCII	IIIVAIALLSGI	WRRRKNKEPSEVD	180					
Qy	181	DAEDKCNMTIENGIPSDPLDMKGG	206							
Db	181	DAEDKCNMTIENGIPSDPLDMKGG	206							

Search completed: June 4, 2004, 08:17:14
Job time : 355.893 secs

GenCore version 5.1.6

Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 4, 2004, 07:49:03 ; Search time 67.7366 Seconds

(without alignments)

884.309 Million cell updates/sec

Title: US-09-997-641-387

Sequence: 1 MLMLFLVTAHAEICQPG.....ENGIPSDPLDMKGILMWS 212

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 225

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%

Maximum Match 100%

Listing first 65000 summaries

Database :

A_Geneseq_29Jan04.*

1:

2:

3:

4:

5:

6:

7:

8:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1102	100.0	212	3	AAY66751 Membrane-
2	1102	100.0	212	3	AAB33447 Human PRO
3	1102	100.0	212	3	AAB24430 Human PRO
4	1102	100.0	212	4	AAB12412 Human PRO
5	1102	100.0	212	4	AAB65274 Human PRO
6	1102	100.0	212	6	ABU58089 Human PRO
7	1102	100.0	212	6	ABU59167 Novel hum
8	1102	100.0	212	6	ABU582679 Human sec
9	1102	100.0	212	6	ABU17856 Novel hum
10	1102	100.0	212	6	ABU60598 Human sec
11	1102	100.0	212	6	ABU13980 Human PRO
12	1102	100.0	212	6	ABU81110 Human PRO
13	1102	100.0	212	6	ABU72565 Novel hum
14	1102	100.0	212	6	ABU66810 Human PRO
15	1102	100.0	212	6	ABU59891 Novel sec
16	1102	100.0	212	6	ABU59314 Human sec
17	1102	100.0	212	6	ABO26011 Human PRO
18	1102	100.0	212	6	ABO25081 Human sec
19	1102	100.0	212	6	ABU59020 Human sec
20	1102	100.0	212	6	ABU92398 Novel hum
21	1102	100.0	212	6	ABU59463 Novel hum
22	1102	100.0	212	6	ABU67086 Human sec
23	1102	100.0	212	6	ABU92229 Novel hum
24	1102	100.0	212	6	ABU10935 Human PRO
25	1102	100.0	212	6	ABU81687 Novel hum

26	1102	100.0	212	6	ABU88626 Human sec
27	1102	100.0	212	6	ABO34140 Human PRO
28	1102	100.0	212	6	ADA46001 Novel hum
29	1102	100.0	212	6	ADA76432 Human PRO
30	1102	100.0	212	6	ADA19082 Human PRO
31	1102	100.0	212	6	ADA61705 Homo sapi
32	1102	100.0	212	6	ADB19490 Novel hum
33	1102	100.0	212	6	ADB28031 Human PRO
34	1102	100.0	212	6	ADA86510 Novel hum
35	1102	100.0	212	6	ADB16074 Human PRO
36	1102	100.0	212	6	ADA37898 Human sec
37	1102	100.0	212	6	ADA47860 Human PRO
38	1102	100.0	212	6	ADA21584 Human sec
39	1102	100.0	212	6	ADA10371 Human sec
40	1102	100.0	212	6	ADA67655 Human PRO
41	1102	100.0	212	6	ADB30662 Human PRO
42	1102	100.0	212	6	ADA85958 Novel hum
43	1102	100.0	212	6	ADA17915 Human PRO
44	1102	100.0	212	6	ADA97170 Human PRO
45	1102	100.0	212	6	ADA79474 Human PRO
46	1102	100.0	212	6	ADA87613 Novel hum
47	1102	100.0	212	6	ADB16815 Human PRO
48	1102	100.0	212	6	ADA28023 Human sec
49	1102	100.0	212	6	ADA91907 Novel hum
50	1102	100.0	212	6	ADB14970 Human PRO
51	1102	100.0	212	6	ADB18931 Novel hum
52	1102	100.0	212	6	ADA94146 Human PRO
53	1102	100.0	212	6	ADB20042 Novel hum
54	1102	100.0	212	6	ADB13354 Human PRO
55	1102	100.0	212	6	ABO43389 Novel hum
56	1102	100.0	212	6	ADA94603 Human sec
57	1102	100.0	212	6	ADA74608 Human PRO
58	1102	100.0	212	6	ADB24841 Human PRO
59	1102	100.0	212	6	ADA82365 Human PRO
60	1102	100.0	212	6	ADA75328 Human PRO
61	1102	100.0	212	6	ADA85406 Novel hum
62	1102	100.0	212	6	ADA84854 Novel hum
63	1102	100.0	212	6	ADB30110 Human PRO
64	1102	100.0	212	6	ADA80638 Human PRO
65	1102	100.0	212	6	ADA75880 Human PRO
66	1102	100.0	212	6	ADA38828 Human sec
67	1102	100.0	212	6	ADA47105 Human PRO
68	1102	100.0	212	6	ADB25401 Human PRO
69	1102	100.0	212	6	ADA93577 Human PRO
70	1102	100.0	212	6	ADB26927 Human PRO
71	1102	100.0	212	6	ADB31214 Human PRO
72	1102	100.0	212	6	ADA92949 Human sec
73	1102	100.0	212	6	ADA61142 Homo sapi
74	1102	100.0	212	6	ADB24289 Human PRO
75	1102	100.0	212	6	ADA96618 Human PRO
76	1102	100.0	212	6	ADA81190 Human PRO
77	1102	100.0	212	6	ADA96066 Human PRO
78	1102	100.0	212	6	ADB26375 Human PRO
79	1102	100.0	212	6	ADB21860 Novel hum
80	1102	100.0	212	7	ADA77639 Human PRO
81	1102	100.0	212	7	ADB18379 Human PRO
82	1102	100.0	212	7	ADA87062 Novel hum
83	1102	100.0	212	7	ADA88165 Novel hum
84	1102	100.0	212	7	ADA46553 Novel hum
85	1102	100.0	212	7	ADB28583 Human PRO
86	1102	100.0	212	7	ADB29135 Human PRO
87	1102	100.0	212	7	ABO53226 Human sec
88	1102	100.0	212	7	ADA77087 Human PRO
89	1102	100.0	212	7	ADA22510 Human sec
90	1102	100.0	212	7	ADA88717 Novel hum
91	1102	100.0	212	7	ADA97722 Human PRO
92	1102	100.0	212	7	ADB27479 Human PRO
93	1102	100.0	212	7	ADB22412 Novel hum
94	1102	100.0	212	7	ABO22596 Human sec
95	1102	100.0	212	7	ADA06676 Human sec
96	1102	100.0	212	7	ADA39369 Human sec
97	1102	100.0	212	7	ADA67103 Human PRO
98	1102	100.0	212	7	ADB22964 Human PRO

99	1102	100.0	212	7	ADB23737	Human PRO	172	1102	100.0	212	7	ADE22355	Human PRO
100	1102	100.0	212	7	AD922459	Novel hum	173	1102	100.0	212	7	ADD79579	Human PRO
101	1102	100.0	212	7	AD922459	Novel hum	174	1102	100.0	212	7	AD922459	Human PRO
102	1102	100.0	212	7	AD922459	Novel hum	175	1102	100.0	212	7	AD922459	Human PRO
103	1102	100.0	212	7	AD922459	Novel hum	176	1102	100.0	212	7	AD922459	Human PRO
104	1102	100.0	212	7	AD922459	Novel hum	177	1102	100.0	212	7	AD922459	Novel hum
105	1102	100.0	212	7	AD922459	Novel hum	178	1102	100.0	212	7	AD922459	Novel hum
106	1102	100.0	212	7	AD922459	Novel hum	179	1102	100.0	212	7	AD922459	Novel hum
107	1102	100.0	212	7	AD922459	Novel hum	180	1102	100.0	212	7	AD922459	Novel hum
108	1102	100.0	212	7	AD922459	Novel hum	181	1102	100.0	212	7	AD922459	Novel hum
109	1102	100.0	212	7	AD922459	Novel hum	182	1102	100.0	212	7	AD922459	Novel hum
110	1102	100.0	212	7	AD922459	Novel hum	183	1102	100.0	212	7	AD922459	Novel hum
111	1102	100.0	212	7	AD922459	Novel hum	184	1102	100.0	212	7	AD922459	Novel hum
112	1102	100.0	212	7	AD922459	Novel hum	185	1102	100.0	212	7	AD922459	Novel hum
113	1102	100.0	212	7	AD922459	Novel hum	186	1102	100.0	212	7	AD922459	Novel hum
114	1102	100.0	212	7	AD922459	Novel hum	187	1102	100.0	212	7	AD922459	Novel hum
115	1102	100.0	212	7	AD922459	Novel hum	188	1102	100.0	212	7	AD922459	Novel hum
116	1102	100.0	212	7	AD922459	Novel hum	189	1102	100.0	212	7	AD922459	Novel hum
117	1102	100.0	212	7	AD922459	Novel hum	190	1102	100.0	212	7	AD922459	Novel hum
118	1102	100.0	212	7	AD922459	Novel hum	191	1102	100.0	212	7	AD922459	Novel hum
119	1102	100.0	212	7	AD922459	Novel hum	192	1102	100.0	212	7	AD922459	Novel hum
120	1102	100.0	212	7	AD922459	Novel hum	193	1102	100.0	212	7	AD922459	Novel hum
121	1102	100.0	212	7	AD922459	Novel hum	194	1102	100.0	212	7	AD922459	Novel hum
122	1102	100.0	212	7	AD922459	Novel hum	195	1102	100.0	212	7	AD922459	Novel hum
123	1102	100.0	212	7	AD922459	Novel hum	196	1102	100.0	212	7	AD922459	Novel hum
124	1102	100.0	212	7	AD922459	Novel hum	197	1102	100.0	212	7	AD922459	Novel hum
125	1102	100.0	212	7	AD922459	Novel hum	198	1102	100.0	212	7	AD922459	Novel hum
126	1102	100.0	212	7	AD922459	Novel hum	199	1102	100.0	212	7	AD922459	Novel hum
127	1102	100.0	212	7	AD922459	Novel hum	200	1102	100.0	212	7	AD922459	Novel hum
128	1102	100.0	212	7	AD922459	Novel hum	201	1102	100.0	212	7	AD922459	Novel hum
129	1102	100.0	212	7	AD922459	Novel hum	202	1102	100.0	212	7	AD922459	Novel hum
130	1102	100.0	212	7	AD922459	Novel hum	203	1102	100.0	212	7	AD922459	Novel hum
131	1102	100.0	212	7	AD922459	Novel hum	204	1102	100.0	212	7	AD922459	Novel hum
132	1102	100.0	212	7	AD922459	Novel hum	205	1102	100.0	212	7	AD922459	Novel hum
133	1102	100.0	212	7	AD922459	Novel hum	206	1073	97.4	222	6	AD922459	Novel hum
134	1102	100.0	212	7	AD922459	Novel hum	207	1073	97.4	222	6	AD922459	Novel hum
135	1102	100.0	212	7	AD922459	Novel hum	208	1073	97.4	222	6	AD922459	Novel hum
136	1102	100.0	212	7	AD922459	Novel hum	209	1073	97.4	222	6	AD922459	Novel hum
137	1102	100.0	212	7	AD922459	Novel hum	210	1073	97.4	222	6	AD922459	Novel hum
138	1102	100.0	212	7	AD922459	Novel hum	211	1073	97.4	222	6	AD922459	Novel hum
139	1102	100.0	212	7	AD922459	Novel hum	212	1073	97.4	222	6	AD922459	Novel hum
140	1102	100.0	212	7	AD922459	Novel hum	213	1066	96.7	223	3	AD922459	Novel hum
141	1102	100.0	212	7	AD922459	Novel hum	214	1066	96.7	223	3	AD922459	Novel hum
142	1102	100.0	212	7	AD922459	Novel hum	215	1048	95.1	222	2	AD922459	Novel hum
143	1102	100.0	212	7	AD922459	Novel hum	216	1048	95.1	222	2	AD922459	Novel hum
144	1102	100.0	212	7	AD922459	Novel hum	217	1048	95.1	222	2	AD922459	Novel hum
145	1102	100.0	212	7	AD922459	Novel hum	218	1048	95.1	222	2	AD922459	Novel hum
146	1102	100.0	212	7	AD922459	Novel hum	219	1048	95.1	222	2	AD922459	Novel hum
147	1102	100.0	212	7	AD922459	Novel hum	220	1048	95.1	222	2	AD922459	Novel hum
148	1102	100.0	212	7	AD922459	Novel hum	221	1048	95.1	222	2	AD922459	Novel hum
149	1102	100.0	212	7	AD922459	Novel hum	222	1048	95.1	222	2	AD922459	Novel hum
150	1102	100.0	212	7	AD922459	Novel hum	223	1048	95.1	222	2	AD922459	Novel hum
151	1102	100.0	212	7	AD922459	Novel hum	224	1040	94.4	222	2	AD922459	Novel hum
152	1102	100.0	212	7	AD922459	Novel hum	225	949	86.1	184	4	AD922459	Novel hum
153	1102	100.0	212	7	AD922459	Novel hum							
154	1102	100.0	212	7	AD922459	Novel hum							
155	1102	100.0	212	7	AD922459	Novel hum							
156	1102	100.0	212	7	AD922459	Novel hum							
157	1102	100.0	212	7	AD922459	Novel hum							
158	1102	100.0	212	7	AD922459	Novel hum							
159	1102	100.0	212	7	AD922459	Novel hum							
160	1102	100.0	212	7	AD922459	Novel hum							
161	1102	100.0	212	7	AD922459	Novel hum							
162	1102	100.0	212	7	AD922459	Novel hum							
163	1102	100.0	212	7	AD922459	Novel hum							
164	1102	100.0	212	7	AD922459	Novel hum							
165	1102	100.0	212	7	AD922459	Novel hum							
166	1102	100.0	212	7	AD922459	Novel hum							
167	1102	100.0	212	7	AD922459	Novel hum							
168	1102	100.0	212	7	AD922459	Novel hum							
169	1102	100.0	212	7	AD922459	Novel hum							
170	1102	100.0	212	7	AD922459	Novel hum							
171	1102	100.0	212	7	AD922459	Novel hum							

ALIGNMENTS

RESULT 1

AAV66751
ID AAV66751 standard; protein; 212 AA.

XX AAV66751;

XX 05-APR-2000 (first entry)

XX Membrane-bound protein PRO1312.

XX Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
pharmaceutical; receptor immunoadhesin; gene mapping.

XX Homo sapiens.

OS

(GETH) GENENTECH INC.

PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
 PI Wood WI, Yuan J;
 XX WPI; 2000-072883/06.
 DR N-PSDB; AA265097.
 XX
 PT Membrane-bound proteins and related nucleotide sequences.
 XX
 PS Claim 12; Fig 278; 822pp; English.

XX The invention provides membrane-bound PRO polypeptides and
 CC polynucleotides encoding them. The PRO sequences of the invention were
 CC identified based on extracellular domain homology screening. The PRO
 CC sequences have homology with proteins including LDL receptors, TIE
 CC ligands and various enzymes. The membrane-bound proteins and receptor
 CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
 CC immunoadhesins, for instance, can be used as therapeutic agents to block
 CC receptor-ligand interactions. The membrane-bound proteins can also be
 CC employed for screening of potential peptide or small molecule inhibitors
 CC of the relevant receptor/ligand interaction. The PRO encoding sequences
 CC are useful as hybridization probes, in chromosome and gene mapping and in
 CC the generation of antisense RNA and DNA. PRO nucleic acid sequences will
 CC also be useful for the preparation of PRO polypeptides, especially by
 CC recombinant techniques
 XX
 SQ Sequence 212 AA;

Query Match 100.0%; Score 1102; DB 3; Length 212;
 Best Local Similarity 100.0%; Pred. No. 5.8e-114;
 Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MLWLLPFLVTAHAEICQPGAENAFKVRISITLALGDKAYAWDTNBEYLFKAWAFPMRK 60
 DB 1 MLWLLPFLVTAHAEICQPGAENAFKVRISITLALGDKAYAWDTNBEYLFKAWAFPMRK 60
 QY 61 VFNREATEISHVLLCNVTQVSFVVTDPKXNHTLPVEVQSAIRMNKRNINNAFFLND 120
 DB 61 VFNREATEISHVLLCNVTQVSFVVTDPKXNHTLPVEVQSAIRMNKRNINNAFFLND 120
 QY 121 QLEFLKIPSTLAPPDPSVPIWIIIFGVIFCIIIVAIALLLSGIWQRXKKEPSEVD 180
 DB 121 QLEFLKIPSTLAPPDPSVPIWIIIFGVIFCIIIVAIALLLSGIWQRXKKEPSEVD 180
 QY 181 DAEDKCNMTTENGIPSPDLNMGKILMPS 212
 DB 181 DAEDKCNMTTENGIPSPDLNMGKILMPS 212

RESULT 2
 AAB33447
 ID AAB33447 standard; protein; 212 AA.
 XX
 AC AAB33447;
 XX
 DT 29-JAN-2001 (first entry)
 XX
 DE Human PRO1312 protein UNQ678 SEQ ID NO:161.

XX Human; immune related disease; diagnosis; antiinflammatory; cardiant;
 KW dermatological; antiarthritic; antirheumatic; immunosuppressive;
 KW haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;
 KW antinaemic; hepatotropic; virocidic; antipsoiatric; antiallergic;
 KW antisthmatic; systemic lupus erythematosus; rheumatoid arthritis;
 KW osteoarthritis; spondyloarthritis; systemic sclerosis; sarcoidosis;
 KW idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;
 KW systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;
 KW autoimmune thrombocytopaenia; immune-mediated renal disease;
 KW demyelinating disease; hepatobiliary disease; Whipple's disease;
 KW inflammatory bowel disease; gluten-sensitive enteropathy;
 KW autoimmune disease; immune-mediated skin disease; allergic disease;
 KW immunological disease; transplantation associated disease;
 KW graft rejection; graft-versus-host-disease.

OS Homo sapiens.
 XX WO2000053758-A2.
 XX
 PD 14-SEP-2000.
 XX
 PF 02-MAR-2000; 2000WO-US005841.
 XX
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99US-0123618P.
 PR 12-MAR-1999; 99US-0123957P.
 PR 13-MAR-1999; 99US-0125775P.
 PR 12-APR-1999; 99US-0128849P.
 PR 20-APR-1999; 99WO-US008615.
 PR 28-APR-1999; 99US-0131445P.
 PR 04-MAY-1999; 99US-0132371P.
 PR 14-MAY-1999; 99US-0134287P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 23-JUN-1999; 99US-0141037P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145638P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021030.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-OCT-1999; 99US-0162506P.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030959.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.

(GETH) GENENTECH INC.

Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W;
 Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V;
 Stewart TA, Tumas D, Watanabe CK, Wood WI, Yan M;
 WPI; 2000-572271/53.
 N-PSDB; AAC58612.

Sixty four PRO polypeptides, useful in the diagnosis and treatment of
 immune related disorders, e.g. systemic lupus erythematosus, rheumatoid
 arthritis, osteoarthritis, thyroiditis and diabetes mellitus.

Claim 33; Fig 68; 309pp; English.

The present invention describes sixty four human PRO proteins which can
 be used in the treatment of immune related diseases. The human PRO
 proteins, anti-PRO antibodies, agonists and antagonists are useful for
 treating and diagnosing immune related disorders. The disorders are
 selected from systemic lupus erythematosus, rheumatoid arthritis,
 osteoarthritis, juvenile chronic arthritis, spondyloarthritis,
 systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's
 syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic
 anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,
 immune-mediated renal disease, demyelinating diseases of the central and

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2004-020236/02.
 DR N-PSDB; ADE24653.
 XX New secreted and transmembrane nucleic acid useful for treating
 PT inflammation, organ failure, atherosclerosis, cardiac injury,
 PT infertility, birth defects, premature aging, acquired immunodeficiency
 syndrome, or cancer.
 XX Claim 12; Fig 482; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

RESULT 202

ADD87479
 ID ADD87479 standard; protein; 212 AA.
 XX AC ADD87479;
 XX DT 29-JAN-2004 (first entry)
 XX DE Human PRO polypeptide #241.
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 OS Homo sapiens.
 XX US2003203439-A1.
 XX 30-OCT-2003.
 XX 17-MAY-2002; 2002US-00147499.
 XX 04-AUG-1998; 98US-0095301P.
 XX 02-JUN-1999; 99WO-US012252.
 XX 30-MAR-2000; 2000US-00380137.
 XX 30-MAR-2000; 2000WO-US009439.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (G5TH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2004-021362/02.
 XX N-PSDB; ADD87478.
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX Claim 12; Fig 482; 648pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 212 AA;
Query Match 100.0%; Score 1102; DB 8; Length 212;
Best Local Similarity 100.0%; Pred No. 5, 8e-114;
Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MLWLLPFLVTAHAEICQCAENAFKRLSIRTFALGDKAYAMDTNEEYLFKAMVAFSMEK 60
DB 1 MLWLLPFLVTAHAEICQCAENAFKRLSIRTFALGDKAYAMDTNEEYLFKAMVAFSMEK 60
QY 61 VPREATEISHVLLCNVTVQVSFWFVVTDPKSNHTLPAVEVQSARIMNKNRINNAFFLND 120
DB 61 VPREATEISHVLLCNVTVQVSFWFVVTDPKSNHTLPAVEVQSARIMNKNRINNAFFLND 120
QY 121 QTLFLKIPSTLAPPDPSVPIWIIIFGVIFCIIIVAIALLILSGIWRKKKPSFVD 180
DB 121 QTLFLKIPSTLAPPDPSVPIWIIIFGVIFCIIIVAIALLILSGIWRKKKPSFVD 180
QY 181 DAEDKCNMTIENGIPSDLMKGGILMMP 212
DB 181 DAEDKCNMTIENGIPSDLMKGGILMMP 212
RESULT 203
AD89345
ID AD89345 standard; protein; 212 AA.
AC AD89345;
DT 29-JAN-2004 (first entry)
DE Human PRO polypeptide #241.
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
OS Homo sapiens.
XX
XX
XX US2003199062-A1.
XX
XX 23-OCT-2003.
XX
XX 17-APR-2002; 2002US-00124823.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012455.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019433.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-0080689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00862636.
PR 19-JUN-2001; 2001US-00866342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
XX
XX WPI: 2004-041360/04.
XX N-PSDB: ADE89344.
XX
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
XX Claim 12; SEQ ID NO 482; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 212 AA;
XX
XX Query Match 100.0%; Score 1102; DB 8; Length 212;
XX Best Local Similarity 100.0%; Pred. No. 5.8e-114;
XX Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MLALLFELVTAHAEIQCPCGAENAFKVLRSIRLTALGDKAYAWDTNEEYLFKAWVAFSNRK 60
DB 1 MLALLFELVTAHAEIQCPCGAENAFKVLRSIRLTALGDKAYAWDTNEEYLFKAWVAFSNRK 60
QY 61 VPNREATEISHVLLCNVTQVSVFWVTDPSKHTLPAVEVQSAIRKNNKINNAPFLND 120
DB 61 VPNREATEISHVLLCNVTQVSVFWVTDPSKHTLPAVEVQSAIRKNNKINNAPFLND 120
QY 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIIAIIIIISGIIWQRRKKNKEPSEVD 180
DB 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIIAIIIIISGIIWQRRKKNKEPSEVD 180
QY 181 DAEDKCNENITENGIPIPSDPLDMKGGILMMP 212
DB 181 DAEDKCNENITENGIPIPSDPLDMKGGILMMP 212
XX
XX RESULT 204
XX ADE18484
XX ID ADE18484 standard; protein; 212 AA.
XX AC ADS18484;
XX XX
XX DT 29-JAN-2004 (first entry)
XX XX
XX DE Human PRO polypeptide #241.
XX XX
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX OS Homo sapiens.
XX
XX FN US2003194794-A1.
XX
XX PD 16-OCT-2003.
XX
XX PF 17-APR-2002; 2002US-00125805.
XX
XX PR 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 14-JUL-1998; 98WO-US014552.
XX PR 28-AUG-1998; 98WO-US017888.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 14-SEP-1998; 98WO-US019177.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022991.
XX PR 29-OCT-1998; 98WO-US022992.
XX PR 01-DEC-1998; 98WO-US024855.
XX PR 01-DEC-1998; 98WO-US025108.
XX PR 05-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 10-MAR-1999; 2000WO-US006319.
XX PR 20-APR-1999; 99WO-US008615.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 08-SEP-1999; 99WO-US020594.
XX PR 13-SEP-1999; 99WO-US020944.
XX PR 15-SEP-1999; 99WO-US021090.
XX PR 15-SEP-1999; 99WO-US021547.
XX PR 05-OCT-1999; 99WO-US023089.


```
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030811.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019592.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001US-00872035.
PR 29-JUN-2001; 2001WO-US021066.
PR 08-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff B, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2004-021079/02.
XX N-PSDB; ADE18483.
XX DR N-PSDB; ADE18483.
XX DR N-PSDB; ADE18483.
XX PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, for use in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX PS Claim 12; SEQ ID NO 482; 638pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting the uptake of
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX the proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 212 AA;

Query Match 100.0%; Score 1102; DB 8; Length 212;
Best Local Similarity 100.0%; Pred. No. 5.8e-114; Indels 0; Gaps 0;
Matches 212; Conservative 0; Mismatches 0;

Qy 1 MLMLLFLVTAIHAELQCPGAENAFKVRSLRTALGDKAVAWDTNEEYLFKAWAFSMRK 60
Db 1 MLMLLFLVTAIHAELQCPGAENAFKVRSLRTALGDKAVAWDTNEEYLFKAWAFSMRK 60
Qy 61 VPREATEISHVLLCNVTQVSFWFVTDPSKNHTLPAVEVQSARMKRINNAFLND 120
Db 61 VPREATEISHVLLCNVTQVSFWFVTDPSKNHTLPAVEVQSARMKRINNAFLND 120
Qy 121 QTLFLKIPSTLAPPDPSVPINIIIFGVIFCIIVAIAMIIILSGIWMRRKKNPESEVD 180
Db 121 QTLFLKIPSTLAPPDPSVPINIIIFGVIFCIIVAIAMIIILSGIWMRRKKNPESEVD 180
Qy 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212
Db 181 DAEDKCNMTIENGIPSDPLDMKGGILMMP 212

RESULT 205
ADE86793
```

ID AD888793 standard; protein; 212 AA.
XX
XX AC AD888793;
XX
XX DT 29-JAN-2004 (first entry)
XX
XX DE Human PRO polypeptide #241.
XX
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX OS Homo sapiens.
XX
XX PN US2003199054-A1.
XX
XX PD 23-OCT-2003.
XX
XX PF 12-APR-2002; 2002US-00121054.
XX
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008415.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 28-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 08-JAN-2000; 2000WO-US000219.
PR 08-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001US-00805520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 03-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2004-041356/04.
XX
XX N-PSDB; AD888792.
XX
XX Novel secreted and transmembrane polypeptides, PRO useful for treating
PT bone disorders, arthritis, heart attack, injuries, tumors, and
PT stimulating release of TNF-alpha from human blood.
XX
XX Claim 12; SEQ ID NO 482; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis

factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems. CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This CC sequence represents a human PRO polypeptide of the invention. Note: The CC sequence data for this patent is also available in electronic format from CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 212 AA;

Query Match 100.0%; Score 1102; DB 8; Length 212;
Best Local Similarity 100.0%; Pred. No. 5,8e-114;
Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWLLFLLVTAIHAELCQGAENAFKVRLSIRTLGDKAYAWDTNTEYLKAMVAFSRK 60
DB 1 MLWLLFLLVTAIHAELCQGAENAFKVRLSIRTLGDKAYAWDTNTEYLKAMVAFSRK 60

QY 61 VFNREATEISHVLLCNVTQVSFWFVVTDPKSNHTLPAVEVQSARIMNKNRINNAFFLND 120
DB 61 VFNREATEISHVLLCNVTQVSFWFVVTDPKSNHTLPAVEVQSARIMNKNRINNAFFLND 120

QY 121 QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRNKNKEPSEVD 180
DB 121 QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRNKNKEPSEVD 180

QY 181 DAEDKCNMTIENGIPSDPLDMKGGILMPPS 212
DB 181 DAEDKCNMTIENGIPSDPLDMKGGILMPPS 212

RESULT 206

AAB88580

ID AAB88580 standard; protein; 222 AA.

XX AAB88580;

XX 04-JUN-2001 (first entry)

XX Human hydrophobic domain containing protein clone HP10720 #64.

XX Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;
XX antianaemic; vulnary; antiulcer; osteopathic; anti-inflammatory;
XX cytostatic; gene therapy; autoimmune disorder; multiple sclerosis;
XX HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;
XX inflammatory bowel disease; nutritional supplement; appetite; vaccine;
XX behavioural characteristic; immune response.

OS Homo sapiens.

XX WO200112660-A2.

PN

XX 22-FEB-2001.
PD
XX
PF 10-AUG-2000; 2000WO-JP005356.
XX
PR 17-AUG-1999; 99JP-00230344.
PR 07-SEP-1999; 99JP-00252551.
PR 01-OCT-1999; 99JP-00281132.
PR 22-OCT-1999; 99JP-00301624.
PR 04-NOV-1999; 99JP-00313877.
XX
PA (SAGA) SAGAMI CHEM RES CENT.
PA (PROT-) PROTEGENE INC.

XX Kato S, Kimura T;

XX WPI; 2001-160059/16.

DR N-PSDB; AAF94460.

XX Human proteins with hydrophobic domains and the DNAs which encode them are useful for treating autoimmune disorders, burns and tumors and for screening novel pharmaceuticals.

XX Claim 1; Page 354-355; 518pp; English.

XX AAF94417 to AAF94516 encode the human proteins given in AAB88557 to AAB88606 (I) which have a hydrophobic domain. (I) have immunosuppressant, anti-HIV, neuroprotective, antianaemic, vulnary, antiulcer, osteopathic, anti-inflammatory and cytostatic activities, and can be used in gene therapy. (I) can be used as pharmaceuticals and as antigens to prepare antibodies. DNA and cDNA (II) encoding (I) can be used as probes for genetic diagnosis and gene sources for gene therapy or for producing (I) in large quantities. Cells containing (II) are used for the detection of ligands or receptors corresponding to membrane or secretory proteins and to screen small molecule novel pharmaceuticals. Antibodies directed to (I) can be used for the detection, quantification and purification of (I). Activities of (I) may include cytokine and cell proliferation/differentiation function, immune stimulating or suppressing activity, haematopoiesis regulating activity, tissue growth activity, activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, receptor/ligand activity and anti-inflammatory activity. (I) and (II) can be used to treat autoimmune disorders e.g. multiple sclerosis, HIV infections, anaemia, burns, ulcers, osteoporosis, inflammatory bowel disease and tumours. (I) and (II) can also be used for wound healing, as nutritional sources or supplements e.g. as amino acid, carbon or nitrogen source, to effect metabolism, catabolism, anabolism, processing and utilisation of dietary fat, protein, carbohydrate, vitamins and minerals, to effect behavioural characteristics, to affect appetite, and can act as antigens in vaccines to raise an immune response to the protein or another material cross-reactive with the protein

XX Sequence 222 AA;

Query Match 97.4%; Score 1073; DB 4; Length 222;

Best Local Similarity 100.0%; Pred. No. 1e-110;

Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWLLFLLVTAIHAELCQGAENAFKVRLSIRTLGDKAYAWDTNTEYLKAMVAFSRK 60

DB 1 MLWLLFLLVTAIHAELCQGAENAFKVRLSIRTLGDKAYAWDTNTEYLKAMVAFSRK 60

QY 61 VFNREATEISHVLLCNVTQVSFWFVVTDPKSNHTLPAVEVQSARIMNKNRINNAFFLND 120

DB 61 VFNREATEISHVLLCNVTQVSFWFVVTDPKSNHTLPAVEVQSARIMNKNRINNAFFLND 120

QY 121 QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRNKNKEPSEVD 180

DB 121 QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRNKNKEPSEVD 180

QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206

DB 181 DAEDKCNMTIENGIPSDPLDMKGG 206

RESULT 207
ADA56986
ID ADA56986 standard; protein; 222 AA.
XX
XX ADA56986;
AC
XX
XX 20-NOV-2003 (first entry)
DT
XX
XX Human secreted protein #269.
DE
XX
XX immunosuppressive; antiinflammatory; antiasthmatic; antiallergic;
KW
XX cytosolic; cerebroprotective; neuroprotective; nootropic;
KW
XX cardiovascular; antiarteriosclerotic; gene therapy;
KW
XX human secreted protein; immune disorder; inflammation;
KW
XX respiratory disorder; cancer; CNS disorder; neurodegenerative disorders;
KW
XX inflammatory bowel disease; nephritis; Crohn's disease; asthma; allergy;
KW
XX multiple sclerosis; ischaemic brain injury; Parkinson's disease;
KW
XX Alzheimer's disease; atherosclerosis; myocarditis; chromosome mapping;
KW
XX triple helix formation; antisense gene therapy; forensic biology.
XX
OS Homo sapiens.
XX
XX WO2002102994-A2.
XX
XX 27-DEC-2002.
PD
XX
XX 19-MAR-2002; 2002WO-US008278.
PF
XX
XX 21-MAR-2001; 2001US-0277340P.
PR
XX
XX 19-JUL-2001; 2001US-0306171P.
PR
XX
XX 13-NOV-2001; 2001US-0331287P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA
XX
XX Rosen CA, Ruben SM;
FI
XX
XX WPI; 2003-167512/16.
DR
XX
XX N-PSDE; ADA56986.
XX
XX New human secreted polypeptides and polynucleotides, useful for
PT
XX diagnosing, treating or preventing e.g. immune disorders, inflammatory
PT
XX conditions, respiratory disorders, cancers, CNS disorders, or
PT
XX neurodegenerative disorders.
XX
XX Claim 13; SEQ ID NO 1176; 1754pp; English.
XX
XX The invention relates to 592 new human secreted polypeptides useful for
CC
XX diagnosing, treating or preventing e.g. immune disorders, inflammatory
CC
XX conditions, respiratory disorders, cancers, CNS disorders, or
CC
XX neurodegenerative disorders, or polypeptides comprising an amino acid
CC
XX sequence at least 95% identical to the new sequences. The polypeptides,
CC
XX antibodies or antibody fragments that bind to the polypeptides, nucleic
CC
XX acids encoding the polypeptides, agonists or antagonists that binds to
CC
XX the polypeptide, are useful in preparing diagnostic or pharmaceutical
CC
XX compositions for diagnosing, treating or preventing an e.g. immune
CC
XX disorders, inflammatory conditions (e.g. inflammatory bowel disease,
CC
XX nephritis or Crohn's disease), respiratory disorders (e.g. asthma and
CC
XX allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders
CC
XX (e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative
CC
XX disorders (e.g. Parkinson's disease or Alzheimer's disease), and
CC
XX cardiovascular disorders (e.g. atherosclerosis or myocarditis). The
CC
XX polynucleotides are useful for chromosome identification, chromosome
CC
XX mapping, for controlling gene expression through triple helix formation
CC
XX or antisense DNA or RNA, in gene therapy, for identifying individuals
CC
XX from minute biological samples, in forensic biology, and as hybridization
CC
XX probes. The polypeptides are useful for as molecular weight markers on
CC
XX sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
CC
XX gels, to raise antibodies, for testing biological activities, and for
CC
XX treating or preventing neural disorders, immune system disorders,
CC
XX muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
CC
XX renal, proliferative and/or cancerous diseases. This sequence corresponds
CC
XX to one of the polypeptide of the invention. Note: The sequence data for

CC this patent did form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
XX
SQ Sequence 222 AA;
Query Match 97.4%; Score 1073; DB 6; Length 222;
Best Local Similarity 100.0%; Pred. No. 1e-110;
Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MWLLPFLVTAIHAELCQGAENAFKRLSIRLTALGDKAYAWDTNEEYLFKAMVAFSMRK 60
DB 1 MWLLPFLVTAIHAELCQGAENAFKRLSIRLTALGDKAYAWDTNEEYLFKAMVAFSMRK 60
QY 61 VPREATEISHVLLCNVTQVSFWFVVTDPKSNHTLPAVEVQSARIMKNKRNINNAFLND 120
DB 61 VPREATEISHVLLCNVTQVSFWFVVTDPKSNHTLPAVEVQSARIMKNKRNINNAFLND 120
QY 121 QTLFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRKKPSEVD 180
DB 121 QTLFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRKKPSEVD 180
QY 181 DAEKCKENMITIENGIPSPDLMDKGG 206
DB 181 DAEKCKENMITIENGIPSPDLMDKGG 206
RESULT 208
ADA40837
ID ADA40837 standard; protein; 222 AA.
XX
XX ADA40837;
AC
XX
XX 20-NOV-2003 (first entry)
DT
XX
XX Human secreted protein.
DE
XX
XX Human; secreted protein; cancer; hyperproliferative disorder;
KW
XX rheumatoid arthritis; autoimmune disorder; haematopoietic disorder;
KW
XX anaemia; allergic reaction; asthma; cardiovascular disorder;
KW
XX wound healing; cytostatic; immunosuppressive; nootropic; neuroprotective;
KW
XX antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory;
KW
XX vulnery; cardiant; gene therapy.
XX
XX Homo sapiens.
OS
XX
XX WO2002102993-A2.
XX
XX 27-DEC-2002.
PD
XX
XX 19-MAR-2002; 2002WO-US008123.
PF
XX
XX 21-MAR-2001; 2001US-0277340P.
PR
XX
XX 19-JUL-2001; 2001US-0306171P.
PR
XX
XX 13-NOV-2001; 2001US-0331287P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA
XX
XX Rosen CA, Ruben SM;
FI
XX
XX WPI; 2003-175238/17.
DR
XX
XX New human secreted proteins and nucleic acid molecules, useful for
PT
XX preparing a diagnostic or pharmaceutical composition for diagnosing,
PT
XX preventing or treating cancer or other hyperproliferative disorder,
PT
XX asthma, allergies or AIDS.
XX
XX Claim 1; SEQ ID NO 1219; 3205pp; English.
PS
XX
XX The invention relates to novel genes ADA39629-ADA40565 and proteins
CC
XX ADA40566-ADA41501 for human secreted proteins, useful for preventing,
CC
XX treating or ameliorating medical conditions e.g. by protein or gene
CC
XX therapy. The polypeptides, nucleic acid molecules, antibodies or their

CC fragments, and agonists or antagonists that bind to the polypeptide are
 CC useful for preparing a diagnostic or pharmaceutical composition for
 CC diagnosing or treating cancer or other hyperproliferative disorder. The
 CC polypeptides and nucleic acid molecules are also useful for detecting,
 CC preventing, diagnosing, prognosticating, treating or ameliorating cancer
 CC or other hyperproliferative disorders including neoplasms, autoimmune
 CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus
 CC erythematosus, multiple sclerosis, autoimmune thyroiditis or haemolytic
 CC anaemia), haematopoietic or haematological disorders (e.g. anaemia,
 CC thrombocytopenia), allergic reactions including asthma or eczema,
 CC inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory
 CC bowel disease or Crohn's disease), neurodegenerative disorders (e.g.
 CC Alzheimer's disease or Parkinson's disease), cardiovascular disorders
 CC (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial,
 CC fungal or viral infections including HIV/AIDS), or wound healing and
 CC disorders of epithelial cell proliferation. The nucleic acids are also
 CC useful for chromosome identification, radiation hybrid mapping or long-
 CC range restriction mapping, as molecular weight markers, or as
 CC hybridization or diagnostic probes. The polypeptides and antibodies are
 CC useful for providing immunological probes for differential identification
 CC of the tissues immunohistochemistry assays. Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 XX Sequence 222 AA;
 SQ

Query Match 97.4%; Score 1073; DB 6; Length 222;
 Best Local Similarity 100.0%; Pred. No. 1e-110;
 Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MLWLLPFLVTAIHAELCQPGAEAFKVRISIRLTALGDKAYAMDTNVEYLFKAWAFSMRK 60
 DB 1 MLWLLPFLVTAIHAELCQPGAEAFKVRISIRLTALGDKAYAMDTNVEYLFKAWAFSMRK 60
 QY 61 VNRREATEISHVLLCNVTQVSFWFVVTDPSPKNHTLPAVEVQSARIMNKRINNAPFLND 120
 DB 61 VNRREATEISHVLLCNVTQVSFWFVVTDPSPKNHTLPAVEVQSARIMNKRINNAPFLND 120
 QY 121 QTLFELKIPSTLAPPDPSVPIIIFGVIFCIIVAIALLILSGIWQRRRNKPESEVD 180
 DB 121 QTLFELKIPSTLAPPDPSVPIIIFGVIFCIIVAIALLILSGIWQRRRNKPESEVD 180
 QY 181 DAEDKCNMTIENGIPSPDLMKGG 206
 DB 181 DAEDKCNMTIENGIPSPDLMKGG 206

RESULT 209

ABR01796
 ID ABR01796 standard; protein; 222 AA.

XX ABR01796;
 XX
 XX
 XX 19-MAY-2003 (first entry)
 DT
 DE Human cancer-related protein, 156P1D4.
 DE
 XX Human; cytostatic; vaccine; cancer; immune response.
 XX
 XX Homo sapiens.
 OS
 FN WO200283921-A2.
 XX
 XX 24-OCT-2002.
 XX
 XX 10-APR-2002; 2002WO-US011654.
 XX
 XX 10-APR-2001; 2001US-0282739P.
 PR 10-APR-2001; 2001US-0283112P.
 PR 25-APR-2001; 2001US-0286630P.
 XX
 XX (AGEN-) AGENSYS INC.

XX Jakobovits A, Challita-Bid PM, Paris M, Ge W, Hubert RS;
 PI Morrison K, Morrison RK, Raitano AB;
 XX WPI; 2003-075555/07.
 DR N-PSDB; ABZ78127.
 XX
 PT New composition comprising a substance that modulates the structure of
 PT proteins and polynucleotides, useful for therapeutic, prognostic and
 PT diagnostic reagents for eliciting cellular or humoral immune response in
 PT cancer patients.
 XX
 PS Claim 12; Fig 2G; 1021pp; English.
 XX
 CC The present invention relates to novel human cancer-related genes and
 CC proteins (ABZ78120-ABZ78168 and ABR01789-ABR01861). The genes and
 CC proteins are useful for eliciting a humoral or cellular immune response.
 CC The genes are useful as probes and primers for the amplification and/or
 CC detection of genes, mRNAs or their fragments, as reagents for the
 CC diagnosis and/or prognosis of cancer, as coding sequences capable of
 CC directing the expression of the protein, as tools for modulating or
 CC inhibiting the expression of genes and/or translation of transcripts, and
 CC as therapeutic agents. The proteins and peptides are useful as
 CC therapeutic, prognostic and diagnostic reagents for cancer
 XX
 SQ Sequence 222 AA;

Query Match 97.4%; Score 1073; DB 6; Length 222;
 Best Local Similarity 100.0%; Pred. No. 1e-110;
 Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MLWLLPFLVTAIHAELCQPGAEAFKVRISIRLTALGDKAYAMDTNVEYLFKAWAFSMRK 60
 DB 1 MLWLLPFLVTAIHAELCQPGAEAFKVRISIRLTALGDKAYAMDTNVEYLFKAWAFSMRK 60
 QY 61 VNRREATEISHVLLCNVTQVSFWFVVTDPSPKNHTLPAVEVQSARIMNKRINNAPFLND 120
 DB 61 VNRREATEISHVLLCNVTQVSFWFVVTDPSPKNHTLPAVEVQSARIMNKRINNAPFLND 120
 QY 121 QTLFELKIPSTLAPPDPSVPIIIFGVIFCIIVAIALLILSGIWQRRRNKPESEVD 180
 DB 121 QTLFELKIPSTLAPPDPSVPIIIFGVIFCIIVAIALLILSGIWQRRRNKPESEVD 180
 QY 181 DAEDKCNMTIENGIPSPDLMKGG 206
 DB 181 DAEDKCNMTIENGIPSPDLMKGG 206

RESULT 210

ADA11613
 ID ADA11613 standard; protein; 222 AA.

XX ADA11613;
 XX
 XX 06-NOV-2003 (first entry)
 DT
 DE Human novel secreted protein, SEQ ID NO 141.
 DE
 XX cancer; inflammation; immune disorder; neurological disorder;
 KW blood clotting disorder; food additive; food preservative;
 KW storage capability; fat content; nutritional component; human;
 KW secreted protein.
 XX
 OS Homo sapiens.
 XX
 XX US2003055236-A1.
 XX
 XX 20-MAR-2003.
 XX
 XX 14-MAR-2002; 2002US-00097065.
 PR 18-DEC-1997; 97US-0068006P.
 PR 18-DEC-1997; 97US-0068007P.

PR 18-DEC-1997; 97US-0068008P.
 PR 18-DEC-1997; 97US-0068053P.
 PR 18-DEC-1997; 97US-0068054P.
 PR 18-DEC-1997; 97US-0068057P.
 PR 18-DEC-1997; 97US-0068064P.
 PR 18-DEC-1997; 97US-0070923P.
 PR 19-DEC-1997; 97US-0068169P.
 PR 19-DEC-1997; 97US-0068365P.
 PR 19-DEC-1997; 97US-0068367P.
 PR 19-DEC-1997; 97US-0068368P.
 PR 19-DEC-1997; 97US-0068369P.
 PR 17-DEC-1998; 98WO-US027059.
 PR 17-JUN-1999; 99US-00334595.
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Moore PA, Ruben SM, Carter KC, Shi Y, Rosen CA, Soppet DR;
 PI Kyaw H, Wei Y, Florence KA, Duan DR, Florence C, Greene JM, Feng P;
 PI Perrie AM, Yu G, Janat F, Ni J;
 XX
 DR WPI: 2003-567105/53.
 DR N-PSDB; ADA11489.
 XX
 PT New secreted HKABT74 nucleic acid molecules and polypeptides, useful for
 PT preventing, treating, or ameliorating a medical condition, such as
 PT cancer, inflammation, immune disorders, neurological and blood clotting
 PT disorders.
 XX
 PS Claim 11; SEQ ID NO 141; 118pp; English.
 XX
 CC The invention relates to an isolated HKABT74 nucleic acid molecule. The
 CC polypeptides, nucleic acids and antibodies are useful for diagnosing a
 CC pathological condition or a susceptibility to a pathological condition,
 CC for preventing, treating, or ameliorating a medical condition, such as
 CC cancer, inflammation and other immune disorders, neurological and blood
 CC clotting disorders. The nucleic acids are also useful for chromosome
 CC identification, radiation hybrid mapping or long-range restriction
 CC mapping. The polypeptides and antibodies are useful for providing
 CC immunological probes for differential identification of the tissues
 CC immunohistochemistry assays. The polypeptide, polynucleotide, agonist or
 CC antagonist may also be used as a food additive or preservative to
 CC increase or decrease storage capabilities, fat content or other
 CC nutritional components. The present sequence represents the amino acid
 CC sequence of a novel human secreted protein. Note: The sequence data for
 CC this patent did not form part of the printed specification but was
 CC obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov.uk/sequence.html?DocID=20030055236.
 XX
 SQ Sequence 222 AA;

 Query Match 97.4%; Score 1073; DB 6; Length 222;
 Best Local Similarity 100.0%; Pred. No. 1e-110;
 Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 MLMLLFLVTAHAEICQPCGAENAFKVRSLRTALGDKAYAWDTNEEYLFKAMVAFSMRK 60
 DB 1 MLMLLFLVTAHAEICQPCGAENAFKVRSLRTALGDKAYAWDTNEEYLFKAMVAFSMRK 60

 QY 61 VPNREATEISHVLLCNVTVQVSFWFVVTDPKNTLPAVEVQSAIRNKNRINNAFFLND 120
 DB 61 VPNREATEISHVLLCNVTVQVSFWFVVTDPKNTLPAVEVQSAIRNKNRINNAFFLND 120

 QY 121 QTLEFLKIPSTLAPPMDPSPIWIIIFGVIFCIIIVAIALLISGIWQRKKKEPSEVD 180
 DB 121 QTLEFLKIPSTLAPPMDPSPIWIIIFGVIFCIIIVAIALLISGIWQRKKKEPSEVD 180

 QY 181 DAEDKCNMTIENGIPSDPLMKGG 206
 DB 181 DAEDKCNMTIENGIPSDPLMKGG 206

 RESULT 211
 ADD37902

ID ADD37902 standard; protein; 222 AA.
 XX
 AC ADD37902;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human secreted protein #85.
 XX
 KW human secreted protein; Antiallergic; Antiinflammatory; Antibacterial;
 KW Anti-HIV; Cytostatic; Immunosuppressive; Hemostatic.
 XX
 OS Homo sapiens.
 XX
 PN WO200290526-A2.
 XX
 PD 14-NOV-2002.
 XX
 PF 19-MAR-2002; 2002WO-US008279.
 XX
 PR 21-MAR-2001; 2001US-0277340P.
 PR 19-JUL-2001; 2001US-0306171P.
 PR 13-NOV-2001; 2001US-0331287P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Ruben SM;
 XX
 DR WPI: 2003-140218/13.
 XX
 XX New human secreted proteins and nucleic acid molecules, useful for
 PT preparing a diagnostic or pharmaceutical composition for diagnosing or
 PT treating allergic or asthmatic disorders, or related immediate
 PT hypersensitivity disorders.
 XX
 PS Claim 1; SEQ ID NO 384; 1323pp; English.
 XX
 CC The present invention relates to an isolated polypeptide or human
 CC secreted protein. The polypeptides, nucleic acid molecules, antibodies or
 CC their fragments, and agonists or antagonists that bind are useful for
 CC preparing a diagnostic or pharmaceutical composition for diagnosing or
 CC treating allergic or asthmatic disorders. The polypeptide is also useful
 CC for identifying a binding partner by contacting the polypeptide with a
 CC binding partner, and determining whether the binding partner increases or
 CC decreases the activity of the polypeptide. The polypeptides and nucleic
 CC acid molecules are also useful for detecting, preventing, diagnosing,
 CC prognosticating, treating or ameliorating inflammatory disorders
 CC neoplastic diseases, wound healing and disorders of epithelial cell
 CC proliferation, immune disorders, cardiovascular disorders, blood-related
 CC disorders, infectious diseases, endocrine disorders, or gastrointestinal
 CC disorders. The nucleic acids are also useful for chromosome
 CC identification, radiation hybrid mapping or long-range restriction
 CC mapping, as molecular weight markers, or as hybridization or diagnostic
 CC probes. The polypeptides and antibodies are useful for providing
 CC immunological probes for differential identification of the tissues
 CC immunohistochemistry assays. The present sequence represents a human
 CC secreted protein.
 XX
 SQ Sequence 222 AA;

 Query Match 97.4%; Score 1073; DB 7; Length 222;
 Best Local Similarity 100.0%; Pred. No. 1e-110;
 Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 MLMLLFLVTAHAEICQPCGAENAFKVRSLRTALGDKAYAWDTNEEYLFKAMVAFSMRK 60
 DB 1 MLMLLFLVTAHAEICQPCGAENAFKVRSLRTALGDKAYAWDTNEEYLFKAMVAFSMRK 60

 QY 61 VPNREATEISHVLLCNVTVQVSFWFVVTDPKNTLPAVEVQSAIRNKNRINNAFFLND 120
 DB 61 VPNREATEISHVLLCNVTVQVSFWFVVTDPKNTLPAVEVQSAIRNKNRINNAFFLND 120

 QY 121 QTLEFLKIPSTLAPPMDPSPIWIIIFGVIFCIIIVAIALLISGIWQRKKKEPSEVD 180

```
Db 121 QTFLEFLKIPSTLAPWDRSPVWIIIFGVIFCIIVAIALLISGIWQRRRKNKEPSEVD 180
QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
Db 181 DAEDKCNMTIENGIPSDPLDMKGG 206

RESULT 212
AAW29670
ID AAW29670 standard; protein; 222 AA.
AC AAW29670;
XX
DT 09-NOV-1998 (first entry)
DE Homo sapiens clone AM42_3 secreted protein.
XX
KW Clone; secreted protein.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 2..14
FT /note= "signal peptide"
XX
PN WO9832853-A2.
XX
PD 30-JUL-1998.
XX
PF 23-JAN-1998; 98WO-US0001396.
XX
PR 24-JAN-1997; 97US-00789789.
XX
PA (GEMV ) GENETICS INST INC.
XX
PI Jacobs K, McCoy JM, Lavallie ER, Racie LA, Merberg D, Treacy M;
PI Spaulding V, Agostino MJ;
XX
DR WPI; 1998-427949/36.
DR N-PSDB; AAV40540.
XX
XX New isolated polynucleotide(s) and secreted proteins - isolated from
PT human foetal kidney, adult brain, adult salivary gland, foetal brain and
PT adult testes cDNA libraries.
XX
PS Claim 15; Page 65-66; 109pp; English.
XX
CC The sequence is that of a secreted protein. Such a protein can have
CC biological activities, e.g. nutritional activity, cytokine and cell
CC proliferation/differentiation activity, immune stimulating or suppressing
CC activity, haematopoiesis regulating activity, tissue growth activity,
CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, cadherin/tumour invasion suppressor activity, tumour inhibition
CC activity, and other activities
XX
SQ Sequence 222 AA;

Query Match 97.1%; Score 1070; DB 2; Length 222;
Best Local Similarity 99.5%; Pred. No. 2.2e-110;
Matches 205; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLWLLFLVTAIHAELCQGAENAFKVRISIRTAGDKAYADTNEEYLFKXAMVAFSMRK 60
Db 1 MLWLLFLVTAIHAELCQGAENAFKVRISIRTAGDKAYADTNEEYLFKXAMVAFSMRK 60
QY 61 VPNREATEISHVLLCNVTVQSFVVTDPKXHTLPFAVEVQSAIRMNKNRINNAPFLND 120
Db 61 VPNREATEISHVLLCNVTVQSFVVTDPKXHTLPFAVEVQSAIRMNKNRINNAPFLND 120
QY 121 QTFLEFLKIPSTLAPWDRSPVWIIIFGVIFCIIVAIALLISGIWQRRRKNKEPSEVD 180
Db 121 QTFLEFLKIPSTLAPWDRSPVWIIIFGVIFCIIVAIALLISGIWQRRRKNKEPSEVD 180
```

```
QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
Db 181 DAEDKCNMTIENGIPSDPLDMKGG 206

RESULT 213
ADEL1757
ID ADEL1757 standard; protein; 222 AA.
XX
AC ADEL1757;
XX
DT 29-JAN-2004 (first entry)
DE Human secreted polypeptide #12.
XX
KW Secreted protein; cancer; liver disorder; hepatitis; neural disorder;
KW Alzheimer's disease; human.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US2003100051-A1.
XX
PD 29-MAY-2003.
XX
PF 10-SEP-2001; 2001US-00948783.
XX
PR 12-MAY-1998; 98US-0085093P.
PR 12-MAY-1998; 98US-0085094P.
PR 12-MAY-1998; 98US-0085105P.
PR 12-MAY-1998; 98US-0085180P.
PR 18-MAY-1998; 98US-0085308P.
PR 18-MAY-1998; 98US-0085920P.
PR 18-MAY-1998; 98US-0085921P.
PR 18-MAY-1998; 98US-0085922P.
PR 18-MAY-1998; 98US-0085923P.
PR 18-MAY-1998; 98US-0085924P.
PR 18-MAY-1998; 98US-0085925P.
PR 18-MAY-1998; 98US-0085927P.
PR 18-MAY-1998; 98US-0085928P.
PR 06-MAY-1999; 99WO-US0009847.
PR 11-SEP-2000; 2000US-0231846P.
PR 28-JUN-2001; 2001US-00892877.
XX
XX (RUBE/) RUBEN S M.
PA (FLOR/) FLORENCE K A.
PA (NIJ/) NI J.
PA (ROSE/) ROSEN C A.
PA (CART/) CARTER K C.
PA (MOOR/) MOORE P A.
PA (OLSE/) OLSEN H S.
PA (SHY/) SHI Y.
PA (YOUN/) YOUNG P B.
PA (WEI/) WEI Y.
PA (BREW/) BREWER L A.
PA (SOPP/) SOPPET D R.
PA (LAF/) LAFLEUR D W.
PA (ENDR/) ENDRESS G A.
PA (EBNE/) EBNER R.
PA (BIRS/) BIRSE C E.
XX
XX Ruben SM, Florence KA, Ni J, Rosen CA, Carter KC, Moore PA;
PI Olsen HS, Shi Y, Young PB, Wei Y, Brewer LA, Soppet DR, Lafleur DW;
PI Endress GA, Ebner R, Birse CE;
XX
XX WPI; 2003-801210/75.
XX
XX New nucleic acid molecule, useful for preparing a medicament for
PT preventing, treating or ameliorating a medical condition e.g. cancer,
PT liver disorders or neural disorders.
XX
```

PS Claim 11; SEQ ID NO 129; 453pp; English.
XX The invention relates to human secreted polypeptides and the
CC polynucleotides encoding them. The sequences are useful for preparing
CC medicaments for preventing, treating or ameliorating medical conditions
CC e.g., cancer, liver disorders such as hepatitis or neural disorders such
CC as Alzheimer's disease. This sequence represents a human secreted
CC polypeptide of the invention.
XX
SQ Sequence 222 AA;

Query Match 96.7%; Score 1066; DB 7; Length 222;
Best Local Similarity 99.5%; Pred. No. 6.3e-110; Indels 0; Gaps 0;
Matches 205; Conservative 0; Mismatches 1;

Qy 1 MLMLFFLVTAHAEELCPQGAENAFKRLSIRLTALGDKAYAWDTNEEYLFKAWAFSMRK 60
Db 1 MLMLFFLVTAHAEELCPQGAENAFKRLSIRLTALGDKAYAWDTNEEYLFKAWAFSMRK 60

Qy 61 VPRREATEISHVLLCNVTQVSFWFVTDPSKNTLPAVEVQSAIRNKNRINNAPFLND 120
Db 61 VPRREATEISHVLLCNVTQVSFWFVTDPSKNTLPAVEVQSAIRNKNRINNAPFLNX 120

Qy 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLLSGIWQRKKKEPSEVD 180
Db 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLLSGIWQRKKKEPSEVD 180

Qy 181 DAEDKCNMTIENGIPSDPLDMKGG 206
Db 181 DAEDKCNMTIENGIPSDPLDMKGG 206

RESULT 214
AAAY76135
ID AAY76135 standard; protein; 223 AA.
XX
AC AAY76135;
XX
DT 23-MAR-2000 (first entry)
XX
DE Human secreted protein encoded by gene 12.
XX
KW Human; secreted protein; cancer; tumour; developmental abnormality;
KW fetal deficiency; blood disorder; immune system disorder; inflammation;
KW autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW digestive disorder; endocrine disorder; infection; AIDS; leukaemia;
KW therapy.
XX
OS Homo sapiens.
XX
DN WO9958660-A1.
XX
PD 18-NOV-1999.
XX
PF 06-MAY-1999; 99WO-US009847.
XX
PR 12-MAY-1998; 98US-0085093P.
PR 12-MAY-1998; 98US-0085094P.
PR 12-MAY-1998; 98US-0085105P.
PR 12-MAY-1998; 98US-0085180P.
PR 18-MAY-1998; 98US-0085906P.
PR 18-MAY-1998; 98US-0085920P.
PR 18-MAY-1998; 98US-0085921P.
PR 18-MAY-1998; 98US-0085922P.
PR 18-MAY-1998; 98US-0085923P.
PR 18-MAY-1998; 98US-0085924P.
PR 18-MAY-1998; 98US-0085925P.
PR 18-MAY-1998; 98US-0085927P.
PR 18-MAY-1998; 98US-0085928P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Florence K, Ni J, Rosen CA, Carter KC, Moore PA;
PI Olsen HS, Shi Y, Young PE, Wei F, Brewer LA, Soppet DR, Lafleur DW;
PI Address GA, Ebner R;
XX
DR WP1; 2000-062296/05.
DR N-PSDB; AA265261.
XX
PT New isolated human genes and the secreted polypeptides they encode,
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX
PS Claim 11; Page 365-366; 475pp; English.
XX
CC AA265250 to AA265350 represent 97 isolated human secreted protein genes.
CC AAY76124 to AAY76223 represent the secreted proteins encoded by the 97
CC human genes. The genes and their corresponding secreted polypeptides are
CC useful for preventing, treating or ameliorating medical conditions, e.g.
CC by protein or gene therapy. Also pathological conditions can be diagnosed
CC by determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new genes. Specific uses are
CC described for each of the 97 genes, based on which tissues they are most
CC highly expressed in, and include developing products for the diagnosis or
CC treatment of cancer, tumours, developmental abnormalities and foetal
CC deficiencies, blood disorders, diseases of the immune system, autoimmune
CC diseases, inflammation, allergies, Alzheimer's and cognitive disorders,
CC schizophrenia, arthritis, asthma, psoriasis, sepsis, skin disorders,
CC atherosclerosis, diabetes, cardiovascular disorders, kidney disorders,
CC digestive/endocrine disorders, infections and AIDS. The polypeptides are
CC also useful for identifying their binding partners. The sequences shown
CC in AAY76224 to AAY76424 represent fragments of the secreted proteins
XX
SQ Sequence 223 AA;

Query Match 96.7%; Score 1066; DB 3; Length 223;
Best Local Similarity 99.5%; Pred. No. 6.3e-110; Indels 0; Gaps 0;
Matches 205; Conservative 0; Mismatches 1;

Qy 1 MLMLFFLVTAHAEELCPQGAENAFKRLSIRLTALGDKAYAWDTNEEYLFKAWAFSMRK 60
Db 1 MLMLFFLVTAHAEELCPQGAENAFKRLSIRLTALGDKAYAWDTNEEYLFKAWAFSMRK 60

Qy 61 VPRREATEISHVLLCNVTQVSFWFVTDPSKNTLPAVEVQSAIRNKNRINNAPFLND 120
Db 61 VPRREATEISHVLLCNVTQVSFWFVTDPSKNTLPAVEVQSAIRNKNRINNAPFLNX 120

Qy 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLLSGIWQRKKKEPSEVD 180
Db 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLLSGIWQRKKKEPSEVD 180

Qy 181 DAEDKCNMTIENGIPSDPLDMKGG 206
Db 181 DAEDKCNMTIENGIPSDPLDMKGG 206

RESULT 215
AAAY04156
ID AAY04156 standard; protein; 222 AA.
XX
AC AAY04156;
XX
DT 16-JUN-1999 (first entry)
XX
DE Human 5' EST secreted protein SEQ ID NO:27.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS Homo sapiens.


```

XX PN WO9906439-A2.
XX PD 11-FEB-1999.
XX PF 31-JUL-1998; 98WO-IB001233.
XX PR 01-AUG-1997; 97US-00904468.
XX PA (GEST ) GENSET.
XX PI Dumas Milne Edwards J, Duclert A, Lacroix B;
XX DR WPI; 1999-153700/13.
XX DR N-PSDB; AAX19983.
XX PT New nucleic acids encoding human secreted proteins - obtained from cDNA
XX PT libraries derived from liver, lung, large intestine, colon, thyroid and
XX PT pancreas tissue.
XX PS Example 28; Page 157-158; 398pp; English.
XX CC AAX40251 to AAX40397 represent 5' expressed sequence tags (ESTs) for
XX CC human secreted proteins, and encode the proteins given in AAX11533 to
XX CC AAX11675, respectively. The proteins given represent the signal peptide
XX CC and an N-terminal fragment of a secreted protein. The nucleic acid
XX CC sequences can be used for producing secreted human gene products. They
XX CC can also be used to develop products for diagnosis and therapy. The
XX CC proteins obtained may have cytokine activity, cell
XX CC proliferation/differentiation activity, haematopoiesis regulating
XX CC activity, tissue growth regulating activity, reproductive hormone
XX CC regulating activity, chemotactic/ chemokinetic activity, haemostatic and
XX CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
XX CC activity, tumour inhibition activity or other activities. The products
XX CC can be used in forensic, gene therapy and chromosome mapping procedures.
XX CC The sequences can also be used for obtaining corresponding promoter
XX CC sequences. The nucleic acids encoding the signal peptide can be used for
XX CC directing extracellular secretion of a polypeptide or the insertion of a
XX CC polypeptide into a membrane, or importing a polypeptide into a cell. The
XX CC present sequence represents the protein from a 5' EST from an example of
XX CC the present invention
XX SQ Sequence 222 AA;

Query Match 95.1%; Score 1048; DB 2; Length 222;
Best Local Similarity 98.1%; Pred. No. 6.3e-108;
Matches 202; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 MLWLLFFLVTAIHAEICQPGAEAFKVLRSIRLTALGDKAYAWDTNBEYLFKAMVAFSMRK 60
DB 1 MLWLLFFLVTAIHAEICQPGAEAFKVLRSIRLTALGDKAYAWDTNBEYLFKAMVAFSMRK 60

QY 61 VFNREATEISHVLLCNVTQVSFWFVTDPSKNHTLPAVEVQSAIRMNKNRINNAPFLND 120
DB 61 VFNREATEISHVLLCNVTQVSFWFVTDPSKNHTLPAVEVQSAIRMNKNRINNAPFLND 120

QY 121 QTLFELKIPSTLAPPDPSVPIIIFGVIFCIIIVAIALLISGIWQRXKNKPSEVD 180
DB 121 QTLFELKIPSTLAPPDPSVPIIIFGVIFCIIIVAIALLISGIWQRXKNKPSEVD 180

QY 181 DASDCKENMTIENGIPSDPLDMKGG 206
DB 181 DASXXCENMTIENGIPSDPLDMKGG 206

RESULT 216
AAW93620
ID AAW93620 standard; protein; 222 AA.
XX AC AAW93620;
XX AC (first entry)
XX UT 21-JUN-1999
XX
```

```

DE Human 5' EST secreted protein clone 58-35-2-F10-FL2.
XX Human; secreted protein; EST; expressed sequence tag; diagnosis;
XX forensic; gene therapy; chromosome mapping; signal peptide;
XX upstream regulatory sequence; cytokine activity; cell proliferation;
XX differentiation; haematopoiesis regulation; tissue growth regulation;
XX reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
XX thrombolytic; anti-inflammatory; tumour inhibition.
XX OS Homo sapiens.
XX PN WO9906551-A2.
XX PD 11-FEB-1999.
XX PF 31-JUL-1998; 98WO-IB001235.
XX PR 01-AUG-1997; 97US-00905133.
XX PA (GEST ) GENSET.
XX PI Dumas Milne Edwards J, Duclert A, Lacroix B;
XX DR WPI; 1999-153781/13.
XX DR N-PSDB; AAX39430.
XX PT New nucleic acids encoding human secreted - proteins obtained from cDNA
XX PT libraries prepared from substantia nigra, cerebellum, surreals and fetal
XX PT brain tissue.
XX PS Example 28; Page 157-158; 434pp; English.
XX CC AAX39440 to AAX39597 represent 5' expressed sequence tags (ESTs) for
XX CC human secreted proteins, and encode the proteins given in AAX11374 to
XX CC AAX11531, respectively. The proteins given represent the signal peptide
XX CC and an N-terminal fragment of a secreted protein. The nucleic acid
XX CC sequences can be used for producing secreted human gene products. They
XX CC can also be used to develop products for diagnosis and therapy. The
XX CC proteins obtained may have cytokine activity, cell
XX CC proliferation/differentiation activity, haematopoiesis regulating
XX CC activity, tissue growth regulating activity, reproductive hormone
XX CC regulating activity, chemotactic/ chemokinetic activity, haemostatic and
XX CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
XX CC activity, tumour inhibition activity or other activities. The products
XX CC can be used in forensic, gene therapy and chromosome mapping procedures.
XX CC The sequences can also be used for obtaining corresponding promoter
XX CC sequences. The nucleic acids encoding the signal peptide can be used for
XX CC directing extracellular secretion of a polypeptide or the insertion of a
XX CC polypeptide into a membrane, or importing a polypeptide into a cell. This
XX CC represents a human 5' EST secreted protein encoded by AAX39430
XX SQ Sequence 222 AA;

Query Match 95.1%; Score 1048; DB 2; Length 222;
Best Local Similarity 98.1%; Pred. No. 6.3e-108;
Matches 202; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 MLWLLFFLVTAIHAEICQPGAEAFKVLRSIRLTALGDKAYAWDTNBEYLFKAMVAFSMRK 60
DB 1 MLWLLFFLVTAIHAEICQPGAEAFKVLRSIRLTALGDKAYAWDTNBEYLFKAMVAFSMRK 60

QY 61 VFNREATEISHVLLCNVTQVSFWFVTDPSKNHTLPAVEVQSAIRMNKNRINNAPFLND 120
DB 61 VFNREATEISHVLLCNVTQVSFWFVTDPSKNHTLPAVEVQSAIRMNKNRINNAPFLND 120

QY 121 QTLFELKIPSTLAPPDPSVPIIIFGVIFCIIIVAIALLISGIWQRXKNKPSEVD 180
DB 121 QTLFELKIPSTLAPPDPSVPIIIFGVIFCIIIVAIALLISGIWQRXKNKPSEVD 180

QY 181 DAEDCKENMTIENGIPSDPLDMKGG 206
DB 181 DAEXXCENMTIENGIPSDPLDMKGG 206
```

RESULT 217

AAV35890
ID AAV35890 standard; protein; 222 AA.

XX AC AAV35890;
XX AC AAV35890;

DT 13-SEP-1999 (first entry)

DE Extended human secreted protein sequence, SEQ ID NO. 27.

KW Secreted protein; human; cytokine; cellular proliferation; cell movement;
KW cellular differentiation; immune system regulator; anti-inflammatory;
KW haematopoiesis regulator; tissue growth regulator; tumour inhibitor;
KW reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;
KW genetic disease.

XX OS Homo sapiens.

XX WO9931236-A2.

XX PD 24-JUN-1999.

XX PF 17-DEC-1998; 98WO-IB002122.

XX PR 17-DEC-1997; 97US-0069957P.

XX PR 09-FEB-1998; 98US-0074121P.

XX PR 13-APR-1998; 98US-0081563P.

XX PR 10-AUG-1998; 98US-0096116P.

XX PA (GEST) GENSET.

XX PI Bougueleret L, Duclert A, Dumas Milne Edwards J;

XX DR WPI; 1999-385906/32.

XX DR N-PSDB; AAX97564.

XX PT New isolated human secreted proteins.

XX PS Example 28; Page 165-166; 516pp; English.

XX CC This sequence is encoded by an extended human secreted protein coding
CC sequence of the invention. The secreted proteins can be used in treating
CC or controlling a variety of human conditions. The secreted proteins may
CC act as cytokines or may affect cellular proliferation or differentiation
CC or may act as immune system regulators, haematopoiesis regulators, tissue
CC growth regulators, regulators of reproductive hormones or cell movement
CC or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or
CC tumour inhibition activity. The DNAs can be used in forensic procedures
CC to identify individuals or in diagnostic procedures to identify
CC individuals having genetic diseases resulting from abnormal expression of
CC the genes corresponding to the extended cDNAs. They are also useful for
CC constructing a high resolution map of the human chromosomes. They can
CC also be used for gene therapy to control or treat genetic diseases

XX SQ Sequence 222 AA;

Query Match

Best Local Similarity 95.1%; Score 1048; DB 2; Length 222;

Matches 202; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 MLLFFLVTAHAEELCPGKAPKVLSTRTALGKAYAWDTNEEYLKAYAFPSNRK 60

DB 1 MLLFFLVTAHAEELCPGKAPKVLSTRTALGKAYAWDTNEEYLKAYAFPSNRK 60

QY 61 VPKREATEISHVLLCNVTRQVRSFVVDTPSKNHTLPAVEVQSAIRMNKRNINNAFFLND 120

DB 61 VPKREATEISHVLLCNVTRQVRSFVVDTPSKNHTLPAVEVQSAIRMNKRNINNAFFLND 120

QY 121 QTLFPLKIPSTLAPMDPSVPIIIFGVIFCIIVAIALLISGIWQRKKNPESEVD 180

DB 121 QTLFPLKIPSTLAPMDPSVPIIIFGVIFCIIVAIALLISGIWQRKKNPESEVD 180

QY 181 DAEDKXCNMTIENGIPSDPLDKGG 206

DB 181 DAEDKXCNMTIENGIPSDPLDKGG 206

RESULT 218

AAV59653

ID AAV59653 standard; protein; 222 AA.

XX AC AAV59653;

XX AC AAV59653;

DT 18-JAN-2000 (first entry)

DE Secreted protein extended EST protein sequence #6.

KW Secreted protein; fingerprint identification technique;

KW chromosome mapping; human; hereditary disease; diagnosis; cancer;

KW hyperlipidaemia; cardiovascular; neurodegenerative disorder; therapy;

KW autoimmune disease; rheumatic disease; embryogenic disorder; myopathy;

KW renal injury; amino aciduria; hypoglycaemia; male rat infertility;

KW hypertension.

XX OS Homo sapiens.

XX WO9940189-A2.

XX PD 12-AUG-1999.

XX PF 09-FEB-1999; 99WO-IB000282.

XX PR 09-FEB-1998; 98US-0074121P.

XX PR 13-APR-1998; 98US-0081563P.

XX PR 10-AUG-1998; 98US-0096116P.

XX PR 04-SEP-1998; 98US-0099273P.

XX PA (GEST) GENSET.

XX PI Bougueleret L, Duclert A, Dumas Milne Edwards J;

XX DR WPI; 1999-600966/51.

XX DR N-PSDB; AAZ40770.

XX PT Extended cDNAs useful for expressing secreted proteins and to obtain
XX specific antibodies.

XX PS Example 28; Page 141-142; 244pp; English.

XX CC This sequence is encoded by a fragment of a nucleic acid sequence of the
CC invention. The invention relates to 70 nucleic acids encoding human
CC secreted proteins. The extended cDNAs (or genomic DNAs obtainable from
CC them) may be used to prepare PCR primers and probes. These are useful for
CC forensic matching or positive identification by DNA sequencing. They may
CC also be used in alternative fingerprint identification techniques.
CC Antibodies against the proteins encoded by the extended cDNAs are useful
CC in identification of tissue types or cell species, as well as identifying
CC tissue specific soluble proteins. The sequences can be used for
CC chromosome mapping and identification of genes associated with hereditary
CC diseases or drug response. Signal sequences from the cDNAs can be used in
CC construction of secretion vectors. Other sequences derived from the
CC extended cDNAs can be used to clone upstream genomic DNA sequences
CC including promoters. This is in turn useful for identifying proteins that
CC interact with promoter sequences. Some of the proteins may be useful in
CC diagnosing and treating several disorders including, but not limited to:
CC cancer, hyperlipidaemia, cardiovascular and neurodegenerative disorders,
CC autoimmune diseases, and rheumatic diseases, embryogenic disorders,
CC hypertension, renal injury, amino acidurias, hypoglycaemia, male rat
CC infertility and myopathies

XX SQ Sequence 222 AA;

Query Match

Best Local Similarity 95.1%; Score 1048; DB 2; Length 222;

Matches 202; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

CC sequences. The nucleic acids encoding the signal peptide can be used for
 CC directing extracellular secretion of a polypeptide or the insertion of a
 CC polypeptide into a membrane, or importing a polypeptide into a cell
 XX
 SQ Sequence 222 AA;

Query Match 95.1%; Score 1048; DB 2; Length 222;
 Best Local Similarity 98.1%; Pred. No. 6.3e-109;
 Matches 202; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 MLWLLFFLVTAHAELCQGAENAFKVRLSIRLTALGDKAYAWDTNVEYLFKAWAFSMRK 60
 DB 1 MLWLLFFLVTAHAELCQGAENAFKVRLSIRLTALGDKAYAWDTNVEYLFKAWAFSMRK 60
 QY 61 VFNREATEISHVLLCNVTQVSFWFVVTDPDSKNHTLPAVEVQSARIMNKNRINNAFFLND 120
 DB 61 VFNREATEISHVLLCNVTQVSFWFVVTDPDSKNHTLPAVEVQSARIMNKNRINNAFFLND 120
 QY 121 QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCIIVAIALLILSGIWQRRRKNKEPSEVD 180
 DB 121 QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCIIVAIALLILSGIWQRRRKNKEPSEVD 180
 QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
 DB 181 DAEXXCENMTIENGIPSDPLDMKGG 206

RESULT 219
 AAY01594
 ID AAY01594 standard; protein; 222 AA.
 AC AAY01594;
 DT 18-JUN-1999 (first entry)
 DE Secreted protein encoded by an extended 5' EST cDNA sequence.
 OS Human; secreted protein; EST; expressed sequence tag; diagnosis;
 XX forensic; gene therapy; chromosome mapping; signal peptide;
 XX upstream regulatory sequence; cytokine activity; cell proliferation;
 XX differentiation; haematopoiesis regulation; tissue growth regulation;
 KW reproductively hormone regulation; chemotactic; chemokinetic; haemostatic;
 KW thrombolytic; anti-inflammatory; tumour inhibition.
 XX Homo sapiens.
 XX WO9906554-A2.
 XX 11-FEB-1999.
 XX 31-JUL-1998; 98WO-IB001238.
 XX 01-AUG-1997; 97US-00905134.
 XX (GENSET) GENSET.
 XX Dumas Milne Edwards J, Duclert A, Lacroix B;
 PI WPI; 1999-153784/13.
 DR N-PSDB; AAX26672.
 XX New nucleic acids encoding human secreted proteins - obtained from cDNA
 PT libraries prepared from kidney, fetal kidney, dystrophic muscle, muscle
 PT and heart tissue.
 XX Example 28; Page 161-161; 622pp; English.
 XX The present sequence is encoded by an extended cDNA sequence derived from
 CC a 5' EST encoding a secreted protein. The specification describes 5'
 CC expressed sequence tags (ESTs, see AAX40826-X41093) for human secreted
 CC proteins (see AAY01602 and AAY11994-Y12260). The proteins given represent
 CC the signal peptide and an N-terminal fragment of a secreted protein. The
 CC nucleic acid sequences can be used for producing secreted human gene
 CC products. They can also be used to develop products for diagnosis and
 CC therapy. The proteins obtained may have cytokine activity, cell
 CC proliferation/differentiation activity, haematopoiesis regulating
 CC activity, tissue growth regulating activity, reproductively hormone
 CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
 CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, tumour inhibition activity or other activities. The products
 CC can be used in forensic, gene therapy and chromosome mapping procedures.
 CC The sequences can also be used for obtaining corresponding promoter

CC sequences. The nucleic acids encoding the signal peptide can be used for
 CC directing extracellular secretion of a polypeptide or the insertion of a
 CC polypeptide into a membrane, or importing a polypeptide into a cell
 XX
 SQ Sequence 222 AA;

Query Match 95.1%; Score 1048; DB 2; Length 222;
 Best Local Similarity 98.1%; Pred. No. 6.3e-109;
 Matches 202; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 MLWLLFFLVTAHAELCQGAENAFKVRLSIRLTALGDKAYAWDTNVEYLFKAWAFSMRK 60
 DB 1 MLWLLFFLVTAHAELCQGAENAFKVRLSIRLTALGDKAYAWDTNVEYLFKAWAFSMRK 60
 QY 61 VFNREATEISHVLLCNVTQVSFWFVVTDPDSKNHTLPAVEVQSARIMNKNRINNAFFLND 120
 DB 61 VFNREATEISHVLLCNVTQVSFWFVVTDPDSKNHTLPAVEVQSARIMNKNRINNAFFLND 120
 QY 121 QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCIIVAIALLILSGIWQRRRKNKEPSEVD 180
 DB 121 QTLFELKIPSTLAPPMDPSVPIWIIIFGVIFCIIVAIALLILSGIWQRRRKNKEPSEVD 180
 QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
 DB 181 DAEXXCENMTIENGIPSDPLDMKGG 206

RESULT 220
 AAY12986
 ID AAY12986 standard; protein; 222 AA.
 AC AAY12986;
 DT 22-JUN-1999 (first entry)
 DE Human secreted protein encoded by 5' EST clone 58-35-2-F10-FL2.
 OS Human; secreted protein; EST; expressed sequence tag; diagnosis;
 XX forensic; gene therapy; chromosome mapping; signal peptide;
 XX upstream regulatory sequence; cytokine activity; cell proliferation;
 XX differentiation; haematopoiesis regulation; tissue growth regulation;
 KW reproductively hormone regulation; chemotactic; chemokinetic; haemostatic;
 KW thrombolytic; anti-inflammatory; tumour inhibition.
 XX Homo sapiens.
 XX WO9906552-A2.
 XX 11-FEB-1999.
 XX 31-JUL-1998; 98WO-IB001236.
 XX 01-AUG-1997; 97US-00905223.
 XX (GENSET) GENSET.
 XX Dumas Milne Edwards J, Duclert A, Lacroix B;
 PI WPI; 1999-153782/13.
 DR N-PSDB; AAX51777.
 XX New isolated brain-derived nucleic acids - used to develop products which
 CC may have cytokine, immune, regulatory, haematopoiesis regulating, anti-
 CC inflammatory or tumour inhibition activity.
 XX Example 28; Page 159-160; 577pp; English.
 XX AAX51787 to AAX52019 represent 5' expressed sequence tags (ESTs) for
 CC human secreted proteins, and encode the proteins given in AAY12987 to
 CC AAY13219, respectively. The proteins given represent the signal peptide
 CC and an N-terminal fragment of a secreted protein. The nucleic acid
 CC sequences can be used for producing secreted human gene products. They
 CC can also be used to develop products for diagnosis and therapy. The

CC proteins obtained may have cytokine activity, cell
 CC proliferation/differentiation activity, haematopoiesis regulating
 CC activity, tissue growth regulating activity, chemokine activity, reproductive hormone
 CC regulating activity, chemotactic/chemokinetic activity, anti-inflammatory
 CC thrombolytic activity, receptor/ligand activity, haemostatic and
 CC activity, tumour inhibition activity or other activities. The products
 CC can be used in forensic, gene therapy and chromosome mapping procedures.
 CC The sequences can also be used for obtaining corresponding promoter
 CC sequences. The nucleic acids encoding the signal peptide can be used for
 CC directing extracellular secretion of a polypeptide or the insertion of a
 CC polypeptide into a membrane, or importing a polypeptide into a cell. This
 CC sequence represents the human secreted protein encoded by 5' EST clone 59
 CC -35-2-F10-FL2

XX SQ Sequence 222 AA;

Query Match 95.1%; Score 1048; DB 2; Length 222;
 Best Local Similarity 98.1%; Pred. No. 6.3e-108;
 Matches 202; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 MLLFLFLVTAIHAELCQPGAENAFKVLRSIRLTALGDKAYAWDTNBEYLPKAMVAFSMRK 60
 Db 1 MLLFLFLVTAIHAELCQPGAENAFKVLRSIRLTALGDKAYAWDTNBEYLPKAMVAFSMRK 60

Qy 61 VPBREATEISHVLICNVTORVSEFWVVDPSKNHTLPAVEVQSAIRMKRINNAFFLND 120
 Db 61 VPBREATEISHVLICNVTORVSEFWVVDPSKNHTLPAVEVQSAIRMKRINNAFFLND 120

Qy 121 QTLEFLKIPSTLAPMPDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRKKNKEPSEVD 180
 Db 121 QTLEFLKIPSTLAPMPDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRKKNKEPSEVD 180

Qy 181 DAEDKCNMTIENGIPSDPLDMKGG 206
 Db 181 DAEXXCENMTIENGIPSDPLDMKGG 206

RESULT 221

RAY25459
 ID AAY25459 standard; protein; 222 AA.

XX AC AAY25459;

XX DT 23-SEP-1999 (first entry)

XX DE Human secreted protein 6 derived from extended cDNA.

XX KW Secreted protein; human; cytostatic; thrombotic; osteopathic; forensic;
 XX KW diagnostic; gene therapy; chromosome mapping; secretion vector.

XX OS Homo sapiens.

XX PN W09925825-A2.

XX PD 27-MAY-1999.

XX PF 13-NOV-1998; 98WO-IB001862.

XX PR 13-NOV-1997; 97US-0066677P.

XX PR 17-DEC-1997; 97US-0089957P.

XX PR 09-FEB-1998; 98US-0074121P.

XX PR 13-APR-1998; 98US-0081563P.

XX PR 10-AUG-1998; 98US-0096116P.

XX PR 04-SEP-1998; 98US-0099273P.

XX PA (GEST) GENSET.

XX PI Bougueleret L, Duclert A, Dumas Milne Edwards J;

XX DR WPI; 1999-347472/29.

XX DR N-PSDB; AAX88191.

XX PT Extended cDNAs encoding secreted proteins.

XX PS

XX Example 28; Page 138; 307pp; English.

CC This invention describes novel nucleic acid sequences of extended cDNAs
 CC (see AAY97813-X97906) which encode human secreted proteins (see AAY36129-
 CC Y36222) and which have cytostatic, thrombotic and osteopathic activity.
 CC The extended cDNAs can be used to express secreted proteins or parts of
 CC them or to obtain antibodies capable of binding to the secreted proteins.
 CC They may also be used in diagnostic, forensic, gene therapy and
 CC chromosome mapping procedures. Uses also include design of expression
 CC vectors and secretion vectors. This sequence represents a secreted
 CC protein derived from extended cDNA which is used in the method of the
 CC invention

XX SQ Sequence 222 AA;

Query Match 95.1%; Score 1048; DB 2; Length 222;
 Best Local Similarity 98.1%; Pred. No. 6.3e-108;
 Matches 202; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 MLLFLFLVTAIHAELCQPGAENAFKVLRSIRLTALGDKAYAWDTNBEYLPKAMVAFSMRK 60
 Db 1 MLLFLFLVTAIHAELCQPGAENAFKVLRSIRLTALGDKAYAWDTNBEYLPKAMVAFSMRK 60

Qy 61 VPBREATEISHVLICNVTORVSEFWVVDPSKNHTLPAVEVQSAIRMKRINNAFFLND 120
 Db 61 VPBREATEISHVLICNVTORVSEFWVVDPSKNHTLPAVEVQSAIRMKRINNAFFLND 120

Qy 121 QTLEFLKIPSTLAPMPDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRKKNKEPSEVD 180
 Db 121 QTLEFLKIPSTLAPMPDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRKKNKEPSEVD 180

Qy 181 DAEDKCNMTIENGIPSDPLDMKGG 206
 Db 181 DAEXXCENMTIENGIPSDPLDMKGG 206

RESULT 222

RAY12680
 ID AAY12680 standard; peptide; 222 AA.

XX AC AAY12680;

XX DT 21-JUN-1999 (first entry)

XX DE Human 5' EST secreted protein.

XX KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
 XX KW forensic; gene therapy; chromosome mapping; signal peptide;
 XX KW upstream regulatory sequence; cytokine activity; cell proliferation;
 XX KW differentiation; haematopoiesis regulation; tissue growth regulation;
 XX KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
 XX KW thrombolytic; anti-inflammatory; tumour inhibition.

XX OS Homo sapiens.

XX PN W09906549-A2.

XX PD 11-FEB-1999.

XX PF 31-JUL-1998; 98WO-IB001231.

XX PR 01-AUG-1997; 97US-00905279.

XX PA (GEST) GENSET.

XX PI Dumas Milne Edwards J, Duclert A, Lacroix B;

XX DR WPI; 1999-153779/13.

XX DR N-PSDB; AAX51449.

XX PT New nucleic acids encoding human secreted proteins - obtained from cDNA
 PT libraries derived from testis, ovary, uterus and spleen tissue.

XX PS Example 28; Page 159-160; 522pp; English.

XX CC AAX51459 to AAX51691 represent 5' expressed sequence tags (ESTs) for

XX CC human secreted proteins, and encode the proteins given in AAY12681 to

XX CC AAY12913, respectively. The proteins given represent the signal peptide

XX CC and an N-terminal fragment of a secreted protein. The nucleic acid

XX CC sequences can be used for producing secreted human gene products. They

XX CC can also be used to develop products for diagnosis and therapy. The

XX CC proteins obtained may have cytokine activity, cell

XX CC proliferation/differentiation activity, haematopoiesis regulating

XX CC activity, tissue growth regulating activity, reproductive hormone

XX CC regulating activity, chemotactic/chemokinetic activity, haemostatic and

XX CC thrombolytic activity, receptor/ligand activity, anti-inflammatory

XX CC activity, tumour inhibition activity or other activities. The products

XX CC can be used in forensic, gene therapy and chromosome mapping procedures.

XX CC The sequences can also be used for obtaining corresponding promoter

XX CC sequences. The nucleic acids encoding the signal peptide can be used for

XX CC directing extracellular secretion of a polypeptide or the insertion of a

XX CC polypeptide into a membrane, or importing a polypeptide into a cell. This

XX CC sequence represents an oligonucleotide used in an example in the

XX CC invention, to the isolate the 5' EST sequences of the invention

XX SQ Sequence 222 AA;

Query Match 95.1%; Score 1048; DB 2; Length 222;

Best Local Similarity 98.1%; Pred. No. 6.3e-108; Indels 0; Gaps 0;

Matches 202; Conservative 0; Mismatches 4;

QY 1 MLWLLFFLVTAHAEICQPGAEAPKVRSLRTALGDKAYADTNEEYLFKAWAFSMRK 60

DB 1 MLWLLFFLVTAHAEICQPGAEAPKVRSLRTALGDKAYADTNEEYLFKAWAFSMRK 60

QY 61 VNRREATEISHVLLCNVTQVSFWFVVTDPSPKNTLPFAVEVQSARMMKNRINNAFFLND 120

DB 61 VNRREATEISHVLLCNVTQVSFWFVVTDPSPKNTLPFAVEVQSARMMKNRINNAFFLND 120

QY 121 QTLFELKIPSTLAPPMDPSVPVWIIIFGVIFCIIIVAIALLISGIWQRRRNKPESEVD 180

DB 121 QTLFELKIPSTLAPPMDPSVPVWIIIFGVIFCIIIVAIALLISGIWQRRRNKPESEVD 180

QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206

DB 181 DAEXXCENMTIENGIPSDPLDMKGG 206

RESULT 223

AAG00014

XX AC AAG00014; standard; protein; 222 AA.

XX DT 06-OCT-2000 (first entry)

XX DE Human secreted protein #3.

XX KW Human; secreted protein; 5' EST; expressed sequence tag; cDNA isolation;

XX KW Gene therapy; chromosome mapping.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Peptide 1..13

FT /label= Signal_peptide

FT Protein 14..222

XX /label= Secreted_protein

XX EP1033401-A2.

XX PD 06-SEP-2000.

XX PF 21-FEB-2000; 2000EP-00200610.

XX

PR 26-FEB-1999; 99US-0122487P.

XX (GBST) GENSET.

XX Dumas Milne Edwards J, Duclert A, Giordano J;

XX WPI; 2000-500381/45.

XX N-PSDB; AAC00012.

XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for

XX obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for

XX diagnostic, forensic, gene therapy and chromosome mapping procedures.

XX Disclosure; SEQ ID NO 5; 71pp + Sequence Listing; English.

XX The present sequence is a human secreted protein. The full length cDNA

XX encoding this protein was obtained from a 5' EST using first and second

XX strand synthesis procedures. 5' ESTs were prepared from total human RNAs

XX or polyA+ RNAs derived from 30 different tissues. EST sequences usually

XX correspond mainly to the 3' untranslated region (UTR) of the mRNA because

XX they are often obtained from oligo-dT primed cDNA libraries. Such ESTs

XX are not well suited for isolating cDNA sequences derived from the 5' ends

XX of mRNAs and even in those cases where longer cDNA sequences have been

XX obtained, the full 5' UTR is rarely included. 5' ESTs are derived from

XX mRNAs with intact 5' ends and can therefore be used to obtain full length

XX cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,

XX gene therapy and chromosome mapping procedures. They are used to obtain

XX upstream regulatory sequences and to design expression and secretion

XX vectors

XX SQ Sequence 222 AA;

Query Match 95.1%; Score 1048; DB 3; Length 222;

Best Local Similarity 98.1%; Pred. No. 6.3e-108; Indels 0; Gaps 0;

Matches 202; Conservative 0; Mismatches 4;

QY 1 MLWLLFFLVTAHAEICQPGAEAPKVRSLRTALGDKAYADTNEEYLFKAWAFSMRK 60

DB 1 MLWLLFFLVTAHAEICQPGAEAPKVRSLRTALGDKAYADTNEEYLFKAWAFSMRK 60

QY 61 VNRREATEISHVLLCNVTQVSFWFVVTDPSPKNTLPFAVEVQSARMMKNRINNAFFLND 120

DB 61 VNRREATEISHVLLCNVTQVSFWFVVTDPSPKNTLPFAVEVQSARMMKNRINNAFFLND 120

QY 121 QTLFELKIPSTLAPPMDPSVPVWIIIFGVIFCIIIVAIALLISGIWQRRRNKPESEVD 180

DB 121 QTLFELKIPSTLAPPMDPSVPVWIIIFGVIFCIIIVAIALLISGIWQRRRNKPESEVD 180

QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206

DB 181 DAEXXCENMTIENGIPSDPLDMKGG 206

RESULT 224

AAY04174

ID AAY04174 standard; protein; 222 AA.

XX AC AAY04174;

XX DT 17-JUN-1999 (first entry)

XX DE Human 5' EST secreted protein SEQ ID NO:27.

XX KW Human; secreted protein; EST; expressed sequence tag; diagnosis;

XX KW forensic; gene therapy; chromosome mapping; signal peptide;

XX KW upstream regulatory sequence; cytokine activity; cell proliferation;

XX KW differentiation; haematopoiesis regulation; tissue growth regulation;

XX KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;

XX KW thrombolytic; anti-inflammatory; tumour inhibition.

XX OS Homo sapiens.

XX PF W09906548-A2.

XX PD 11-FEB-1999.
 XX 31-JUL-1998; 98WO-IB001222.
 XX 01-AUG-1997; 97US-00905135.
 XX (GEST) GENSET.
 XX Dumas Milne Edwards J, Duclert A, Lacroix B;
 XX WPI; 1999-153778/13.
 XX N-PSDB; AAX30083.
 XX New nucleic acids encoding human secreted proteins - obtained from cDNA
 XX libraries prepared from e.g. liver, ovary, brain, prostate, kidney, lung,
 XX umbilical cord, placenta and colon tissue.
 XX Example 28; Page 174-175; 824pp; English.
 XX
 CC AAX41094 to AAX41347 represent 5' expressed sequence tags (ESTs) for
 CC human secreted proteins, and encode the proteins given in AAY12261 to
 CC AAY12514, respectively. The proteins given represent the signal peptide
 CC and an N-terminal fragment of a secreted protein. The nucleic acid
 CC sequences can be used for producing secreted human gene products. They
 CC can also be used to develop products for diagnosis and therapy. The
 CC proteins obtained may have cytokine activity, cell
 CC proliferation/differentiation activity, haematopoiesis regulating
 CC activity, tissue growth regulating activity, reproductive hormone
 CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
 CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, tumour inhibition activity or other activities. The products
 CC can be used in forensic, gene therapy and chromosome mapping procedures.
 CC The sequences can also be used for obtaining corresponding promoter
 CC sequences. The nucleic acids encoding the signal peptide can be used for
 CC directing extracellular secretion of a polypeptide or the insertion of a
 CC polypeptide into a membrane, or importing a polypeptide into a cell. The
 CC present sequence represents the protein from a 5' EST from an example of
 CC the present invention
 XX SQ Sequence 222 AA;

Query Match 94.4%; Score 1040; DB 2; Length 222;
 Best Local Similarity 97.6%; Pred. No. 4.9e-107;
 Matches 201; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 1 MLWLLFLVTAIHAELCQPGAEAFKVRSLRTALGDKAYAWDTNTEYLFKAWAFSMRK 60
 DB 1 MLWLLFLVTAIHAELCQPGAEAFKVRSLRTALGDKAYAWDTNTEYLFKAWAFSMRK 60
 QY 61 VFNREATEISHVLLCNVTQVSFWFVVTDPKSHHTLPAVEVQSAIRMNKRINNAPFLND 120
 DB 61 VFNREATEISHVLLCNVTQVSFWFVVTDPKSHHTLPAVEVQSAIRMNKRINNAPFLND 120
 QY 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKPSSEVD 180
 DB 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKPSSEVD 180
 QY 181 DAEXKCNMTIENGIPSDPLDMKG 206
 DB 181 DAEXKCNMTIENGIPSDPLDMKG 206

RESULT 225
 AAM23565
 ID AAM23565 standard; protein; 184 AA.
 XX
 AC AAM23565;
 XX
 DT 12-OCT-2001 (first entry)
 XX
 DE Human EST encoded protein SEQ ID NO: 1090.
 XX

KW Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
 KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
 KW diagnostics; forensic test; gene mapping; genetic disorder; biodiversity;
 XX gene therapy; nutrition.
 XX Homo sapiens.
 XX OS
 XX WO200154477-A2.
 XX PD 02-AUG-2001.
 XX 25-JAN-2001; 2001WO-US002687.
 XX 25-JAN-2000; 2000US-00491404.
 XX 17-JUL-2000; 2000US-00617746.
 XX 03-AUG-2000; 2000US-00631451.
 XX 15-SEP-2000; 2000US-00663870.
 XX (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;
 PI Cao Y, Drmanac RA, Zhang J, Werhman T;
 XX
 DR WPI; 2001-476164/51.
 DR N-PSDB; AAM98224.
 XX
 PT isolated polypeptide for treatment of diseases, diagnostics, raising
 PT antibodies and research use.
 PT
 PS Claim 20; Page 819-820; 1275pp; English.
 XX
 CC The present invention provides the protein and coding sequences of novel
 CC proteins from a variety of organisms, including human, dog, cat, horse,
 CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
 CC urchin and tomato. These were derived from expressed sequence tags (ESTs)
 CC from the organism of interest. They can be used in diagnostics,
 CC forensics, gene mapping, identification of mutations, to assess
 CC biodiversity and for nutritional purposes. The present sequence is a
 CC protein of the invention
 XX SQ Sequence 184 AA;

Query Match 86.1%; Score 949; DB 4; Length 184;
 Best Local Similarity 99.5%; Pred. No. 5e-97;
 Matches 183; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MLWLLFLVTAIHAELCQPGAEAFKVRSLRTALGDKAYAWDTNTEYLFKAWAFSMRK 60
 DB 1 MLWLLFLVTAIHAELCQPGAEAFKVRSLRTALGDKAYAWDTNTEYLFKAWAFSMRK 60
 QY 61 VFNREATEISHVLLCNVTQVSFWFVVTDPKSHHTLPAVEVQSAIRMNKRINNAPFLND 120
 DB 61 VFNREATEISHVLLCNVTQVSFWFVVTDPKSHHTLPAVEVQSAIRMNKRINNAPFLND 120
 QY 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKPSSEVD 180
 DB 121 QTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWORRRKNKPSSEVD 180
 QY 181 DAED 184
 DB 181 DAEE 184

Search completed: June 4, 2004, 07:54:58
 Job time : 88.7366 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 4, 2004, 07:49:03 ; Search time 24.8195 Seconds
(without alignments)
440.972 Million cell updates/sec

Title: * US-09-997-641-387
Perfect score: 1102
Sequence: 1 MLWLLFFLYTAHAEICQPG.....ENGIPSDPLDMKGILMPS 212

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 0

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	DB ID	Description

No matches found

Search completed: June 4, 2004, 07:56:19
Job time : 27.3195 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 4, 2004, 07:49:03 ; Search time 47.5707 Seconds
(without alignments)
1406.114 Million cell updates/sec

Title: US-09-997-641-387

Perfect score: 1102

Sequence: 1 MLWLLFLVTAIHAEIQCQPG.....ENGIPSDPLDMKGGILMWPS 212

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 3

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%

Maximum Match 100%

Listing first 65000 summaries

Database :

SPTREMBL 25:*

1: sp_archaea:*

2: sp_bacteria:*

3: sp_fungi:*

4: sp_human:*

5: sp_invertebrate:*

6: sp_mammal:*

7: sp_mhc:*

8: sp_organelle:*

9: sp_phage:*

10: sp_plant:*

11: sp_podent:*

12: sp_virus:*

13: sp_vertebrate:*

14: sp_unclassified:*

15: sp_rvirus:*

16: sp_bacteriopl:*

17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	DB ID	Description
1	1073	97.4	222	4 Q9HBJ8	Q9hbj8 homo sapien
2	928	84.2	222	11 Q9ESG4	Q9esg4 mus musculus
3	921	83.6	222	11 Q9ESG3	Q9esg3 rattus norv

SUMMARIES

ALIGNMENTS

RESULT 1
Q9HBJ8 ID Q9HBJ8 PRELIMINARY; PRT; 222 AA.
AC Q9HBJ8;
DT 01-MAR-2001 (T-EMBLrel. 16, Created)
DT 01-MAR-2001 (T-EMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (T-EMBLrel. 25, Last annotation update)
DE Kidney-specific membrane protein NX-17 (Hypothetical protein) (NX17

DE Homo sapiens (Human).
OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1] _
RP SEQUENCE FROM N.A.
RX MEDLINE=21264468; PubMed=11278314;
RA Zhang H., Wada J., Hida K., Teuchiya Y., Hiragushi K., Shikata K.,
Wang H., Lin S., Kanwar Y.S., Makino H.,
"Collectrin, a Collecting Duct-specific Transmembrane Glycoprotein, Is
a Novel Homolog of ACE2 and Is Developmentally Regulated in Embryonic
Kidneys.";
RL J. Biol. Chem. 276:17132-17139(2001).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh P.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong J.,
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
Krywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
Jones S.J., Marra M.A.;
"Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Bone marrow, Colon, and Kidney;
RA Strausberg R.;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF229179; AAG09466.1; -
DR EMBL; BC015099; AAHL5099.1; -
DR EMBL; BC014317; AAHL4317.1; -
DR EMBL; BC050606; AAH50606.1; -
KW Hypothetical protein.
SQ SEQUENCE 222 AA; 25235 MW; 52C0ED522134ED05 CRC64;
Query Match 97.4%; Score 1073; DB 4; Length 222;
Best Local Similarity 100.0%; Pred. No. 2.7e-105;
Matches 206; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MLWLLFLVTAIHAEIQCQPGAEAFKVRISIRFALGDKAYAWDTNEEYLFKANVAFSMRK 60
Db 1 MLWLLFLVTAIHAEIQCQPGAEAFKVRISIRFALGDKAYAWDTNEEYLFKANVAFSMRK 60
Qy 61 VPNEATEISHVLLCNVTVQVSFVFTDPSKNTLPAVEVQSAIRMKRINNAFPLND 120
Db 61 VPNEATEISHVLLCNVTVQVSFVFTDPSKNTLPAVEVQSAIRMKRINNAFPLND 120
Qy 121 QTFLEFLKIPSTLAPMDPSVPIWIIIFGVIFCIIVAIALLILSGTWQRKKKEPSEVD 180
Db 121 QTFLEFLKIPSTLAPMDPSVPIWIIIFGVIFCIIVAIALLILSGTWQRKKKEPSEVD 180
Qy 181 DAEDKCNMTIENGIPSDPLDMKGG 206
Db 181 DAEDKCNMTIENGIPSDPLDMKGG 206
RESULT 2
Q9ESG4

Q9ESG4 PRELIMINARY; PRT; 222 AA.
 Q9ESG4;
 01-MAR-2001 (T-EMBLrel. 16, Created)
 01-MAR-2001 (T-EMBLrel. 16, Last sequence update)
 01-JUN-2003 (T-EMBLrel. 24, Last annotation update)
 Kidney-specific membrane protein NX-17 (061000870Rik protein).
 NX17 OR 061000870Rik.
 Mus musculus (Mouse).
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 [1]
 SEQUENCE FROM N.A.
 STRAIN=ICR;
 MEDLINE=99362608; PubMed=10432194;
 Zhang H., Wada J., Kanwar Y.S., Tsuchiyama Y., Hiragushi K., Hida K.,
 Shikata K., Makino H.;
 "Screening for genes up-regulated in 5/6 nephrectomized mouse
 kidney.";
 Kidney Int. 56:549-558(1999).
 [2]
 SEQUENCE FROM N.A.
 STRAIN=C57BL/6J; TISSUE=Kidney;
 MEDLINE=21085660; PubMed=11217851;
 Kawai J., Shingawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 Akizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yananaka I.,
 Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
 Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 Fleischmann W., Gaasterland T., Gliss C., King B., Kochiwa H.,
 Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
 Schriml L.M., Staubli F., Suzuki R., Tonita M., Wagner L., Washio T.,
 Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
 Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
 Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
 Gustincich S., Hill D., Hofmann J., Hume D.A., Kamiya M., Lee N.H.,
 Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
 Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
 Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
 Suzuki H., Toyokata K., Wang K.H., Weitz C., Whitaker C., Wilming L.,
 Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohseki S.,
 Hayashizaki Y.;
 "Functional annotation of a full-length mouse cDNA collection.";
 Nature 409:685-690(2001).
 [3]
 SEQUENCE FROM N.A.
 STRAIN=FVB/N; TISSUE=Kidney;
 MEDLINE=22388257; PubMed=12477932;
 Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
 Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
 Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
 Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 Richards S., Worley K.C., Hale S.S., Garcia A.M., Gay L.J., Rulyk S.W.,
 Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 Krzywicki M.I., Skalska U., Smallus D.E., Schnerch A., Schein J.E.,
 Jones S.J., Marra M.A.;
 "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences.";
 Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 [4]
 SEQUENCE FROM N.A.
 STRAIN=FVB/N; TISSUE=Kidney;
 Strausberg R.;
 Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.

DR EMBL; AF178085; AAG09306.1; -;
 DR EMBL; AK020337; BAB2022.1; -;
 DR EMBL; BC049912; BAH49912.1; -;
 DR MGD; MGI:1926234; NX17;
 SQ SEQUENCE 222 AA; 25070 MW; C07E732CE92935A9 CRC64;
 Query Match 84.2%; Score 928; DB 11; Length 222;
 Best Local Similarity 84.5%; Pred. No. 6e-90;
 Matches 174; Conservative 15; Mismatches 17; Indels 0; Gaps 0;
 QY 1 MLWLLFFVLTTHAELCQGAENAFKVLRSIRTAIGDKAVADTNEEYLFKAMVAFSMRK 60
 DB 1 MLWLLFFVLTTHAELCQGAENAFKVLRSIRTAIGDKAVADTNEEYLFKAMVAFSMRK 60
 QY 61 VFNREATEISHVLLCNVTRQVTFWVVDPSKNHTLPAVEVQSAIRMKRINNAFFLND 120
 DB 61 VFNREATEISHVLLCNVTRQVTFWVVDPSKNHTLPAVEVQSAIRMKRINNAFFLND 120
 QY 121 QTLEFLKIPSTLAPMDPSVPVWIIIFGVIFCIIVVAIIALLLSGIWQRKRNKPESEVD 180
 DB 121 HTLEFLKIPSTLAPMDPSVPVWIIIFGVIFCIIVVAIIALLLSGIWQRKRNKPESEVD 180
 QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
 DB 181 DAEDKCNMTIENGIPSDPLDMKGG 206
 RESULT 3
 Q9ESG3 PRELIMINARY; PRT; 222 AA.
 ID Q9ESG3;
 AC Q9ESG3;
 DT 01-MAR-2001 (T-EMBLrel. 16, Created)
 DT 01-MAR-2001 (T-EMBLrel. 16, Last sequence update)
 DE Kidney-specific membrane protein NX-17.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 NCBI_TaxID=10116;
 [1]
 SEQUENCE FROM N.A.
 RC STRAIN=Sprague-Dawley;
 RX MEDLINE=99362608; PubMed=10432194;
 RA Zhang H., Wada J., Kanwar Y.S., Tsuchiyama Y., Hiragushi K., Hida K.,
 RA Shikata K., Makino H.;
 RT "Screening for genes up-regulated in 5/6 nephrectomized mouse
 kidney.";
 RL Kidney Int. 56:549-558(1999).
 DR EMBL; AF178086; AAG09307.1; -;
 SQ SEQUENCE 222 AA; 25226 MW; 7P4B166AE344F855 CRC64;
 Query Match 83.6%; Score 921; DB 11; Length 222;
 Best Local Similarity 84.5%; Pred. No. 3.3e-89;
 Matches 174; Conservative 13; Mismatches 19; Indels 0; Gaps 0;
 QY 1 MLWLLFFVLTTHAELCQGAENAFKVLRSIRTAIGDKAVADTNEEYLFKAMVAFSMRK 60
 DB 1 MLWLLFFVLTTHAELCQGAENAFKVLRSIRTAIGDKAVADTNEEYLFKAMVAFSMRK 60
 QY 61 VFNREATEISHVLLCNVTRQVTFWVVDPSKNHTLPAVEVQSAIRMKRINNAFFLND 120
 DB 61 VFNREATEISHVLLCNVTRQVTFWVVDPSKNHTLPAVEVQSAIRMKRINNAFFLND 120
 QY 121 QTLEFLKIPSTLAPMDPSVPVWIIIFGVIFCIIVVAIIALLLSGIWQRKRNKPESEVD 180
 DB 121 HTLEFLKIPSTLAPMDPSVPVWIIIFGVIFCIIVVAIIALLLSGIWQRKRNKPESEVD 180
 QY 181 DAEDKCNMTIENGIPSDPLDMKGG 206
 DB 181 DAEDKCNMTIENGIPSDPLDMKGG 206
 Search completed: June 4, 2004, 07:50:54

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 4, 2004, 07:49:03 ; Search time 44.4293 Seconds
(without alignments)
1406.114 Million cell updates/sec

Title: US-09-997-641-387_COPY_15_212
Perfect score: 1029
Sequence: 1 ELCQPGAEAFKVLRSIRTA.....ENGIPSDPLDMKGGILMPS 198

Scoring table:
BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 3

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database : SPTREMBL_25:
1: sp_archaea:
2: sp_bacteria:
3: sp_fungi:
4: sp_human:
5: sp_invertebrate:
6: sp_mammal:
7: sp_mhc:
8: sp_organelle:
9: sp_phage:
10: sp_plant:
11: sp_rodent:
12: sp_virus:
13: sp_vertebrate:
14: sp_unclassified:
15: sp_rvirus:
16: sp_bacteriap:
17: sp_archaeap:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1000	97.2	222	4	Q9HBJ8
2	864	84.0	222	11	Q9ESG4
3	857	83.3	222	11	Q9ESG3

ALIGNMENTS

RESULT 1
Q9HBJ8
ID Q9HBJ8 PRELIMINARY; PRT; 222 AA.
AC Q9HBJ8;
DT 01-MAR-2001 (TRENBERLrel. 16, Created)
DT 01-MAR-2001 (TRENBERLrel. 16, Last sequence update)
DT 01-OCT-2003 (TRENBERLrel. 25, Last annotation update)
DE Kidney-specific membrane protein NK-17 (Hypothetical protein) (NK17)

us-09-997-641-387_copy_15_212.jun4.rspt

Tue Jun 8 07:19:25 2004

Job time : 47.4293 secs